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Biallelic inactivating mutations of the 
transcription factor 1 gene (TCF1), encoding 
hepatocyte nuclear factor 1α (HNF1α), were 
identified in 50% of hepatocellular adenomas 
(HCA) phenotypically characterized by a 
striking steatosis. To understand the 
molecular basis of this aberrant lipid storage, 
we performed a microarray transcriptome 
analysis validated by quantitative RT-PCR, 
western-blotting and lipid profiling. In 
mutated HCA, we showed a repression of 
gluconeogenesis coordinated with an 
activation of glycolysis, citrate shuttle and 
fatty acid synthesis predicting elevated rates 
of lipogenesis. Moreover, the strong 
dowregulation of L-FABP suggests that 
impaired fatty acid trafficking may also 
contribute to the fatty phenotype. In addition, 
transcriptional profile analysis of the 
observed deregulated genes in non-HNF1α-
mutated HCA as well as in non-tumor livers 
allowed us to define a specific signature of the 
HNF1α-mutated HCA. In theses tumors, lipid 
composition was dramatically modified 
according to the transcriptional deregulations 
identified in the fatty acid synthetic pathway. 
Surprisingly, lipogenesis activation did not 
operate through SREBP-1 and ChREBP that 
were repressed. We conclude that steatosis in 
HNF1α-mutated HCA results mainly from an 
aberrant promotion of lipogenesis that is 
linked to HNF1α inactivation and that is 
independent of both SREBP-1 and ChREBP 
activation. Finally, our findings have potential 
clinical implications since lipogenesis can be 
efficiently inhibited by targeted therapies. 
Hepatocyte nuclear factor 1-α (HNF1α) 
is a transcription factor that controls the 
expression of liver-specific genes, such as β-
fibrinogen, α1-antitrypsin and albumin (1). 
Heterozygous germline mutations in the gene 
encoding HNF1α (TCF1) are responsible for an 
autosomal dominant form of non-insulin-
dependent diabetes mellitus called maturity onset 
diabetes of the young type 3 (MODY3), in which 
subjects usually develop hyperglycemia before 
25 years of age (2). More recently, we identified 
HNF1α as a tumor suppressor gene involved in 
human liver tumorigenesis, since we found 
biallelic inactivating mutations of this gene in 
50% of hepatocellular adenomas (HCA) and in 
rare cases of well-differentiated hepatocellular 
carcinomas developed in the absence of cirrhosis 
(3). HCA are rare benign primary liver tumors 
closely related to oral contraceptive intake (4).  
Recently, in a comprehensive analysis of 
genotype-phenotype correlations in a large series 
of 96 HCA, we showed that HNF1α mutations 
define an homogeneous group of tumors 
phenotypically characterized by the recurrent 
presence of a marked steatosis (5). To get insight 
into the underlying molecular mechanisms that 
drive the fatty phenotype in human HNF1α-
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mutated HCA, we performed a transcriptome 
analysis using cDNA and Affymetrix 
microarrays. Gene expression profiles were 
compared between non-tumor livers and 
HNF1α-mutated HCA. Among the differentially 
expressed genes we focused our analysis on 
genes involved in lipid homeostasis and we 
searched for a possible alteration in fat transport, 
degradation and synthesis processes. 
Transcriptomic deregulations were further 
validated in an additional series of tumors, but 
also at the protein level and we analyzed the 
precise composition of accumulated lipids. 
EXPERIMENTAL PROCEDURES 
Patients and samples. A series of 40 HCA, 25 
non steatotic non-tumor livers and 11 steatotic 
non-tumor livers were collected in 9 French 
surgery departments from 1992 to 2004. Liver 
tissues were immediately frozen in liquid 
nitrogen and stored at -80°C until used for 
molecular studies. Among the 38 patients with 
an HCA, the sex ratio (M:F) was 1:9 and the 
mean age was 37 (median=37 years ranging 
from 14 to 56). All the patients were recruited in 
accordance with French law and institutional 
ethical guidelines. The study was approved by 
the ethical committee of Hôpital Saint-Louis, 
Paris, France. All HCA were screened for 
HNF1α and ß-catenin mutation, pathological 
slides were reviewed and all HCA were 
classified as previously described (5). Twenty 
five HCA from 23 patients were HNF1α-
mutated, 11 demonstrated steatosis in more than 
2/3 of hepatocytes, 8 in 1/3 to 2/3 of hepatocytes, 
3 in less than 1/3 and 3 were not steatotic. 
Fifteen HCA had no mutations in HNF1α, four 
of them were β-catenin mutated, five were 
inflammatory and 9 demonstrated steatosis. Non-
tumor liver tissues were taken from patients 
resected with primary liver tumors developed in 
the absence of cirrhosis. Steatotic non-tumor 
livers demonstrated lipid storage either in more 
than 2/3 of hepatocytes (four cases) or in 1/3 to 
2/3 of hepatocytes (7 cases), and were of various 
etiologies: HCV (one case), dysmetabolic 
syndrome (6 cases), alcohol (three cases), and 
unknown etiology (one case).  
Microarray analysis. Total RNA was extracted 
from frozen tissues using Qiagen RNeasy kits 
(Qiagen) according to the manufacturer’s 
instructions. RNA integrity was assessed using 
RNA 6000 nano chips and the Agilent 2100 
Bioanalyzer. RNA quality control was performed 
as previously described (6). Transcriptional 
profiling of HNF1α-mutated HCA and non-
tumor liver tissues was performed using two 
different microarray approches. MIAME-
compliant data (7) have been deposited in Gene 
Expression Omnibus (GEO) at NCBI 
(http://www.ncbi.nlm.nih.gov/geo/) and are 
accessible through GEO Series accession number 
GSExxxx and GSExxxx. Detailed procedure of 
analysis is provided in the supplemental 
experimental procedures. 
Quantitative RT-PCR. Quantitative RT-PCR was 
performed as previously described (8) using pre-
designed primers and probe sets from Applied 
Biosystems for the detection of R18S, FABP1, 
PCK1, PCK2, FBP1, G6PT1, GCK, GCKR, GPI, 
ME1, MDH1, ACLY, PKLR, PKM2 (detection of 
both PKM1 and PKM2 transcripts), ACACA, 
FASN, ELOVL1, ELOVL2, ELOVL5, SCD, 
FADS1, FADS2, SREBP-1 (detection of both 
SREBP-1a and SREBP-1c isoforms), SREBP-1a, 
CHREBP, PPARα, PPARγ, LXRα and HNF4α. 
Ribosomal 18S (R18S) was used for the 
normalization of expression data. The relative 
amount of measured mRNA in samples, was 
determined using the 2-∆∆CT method where ∆∆CT 
= (CTtarget-CTR18S)sample - (CTtarget-CTR18S)calibrator. 
Final results were expressed as the n-fold 
differences in target gene expression in tested 
samples compared to the mean expression value 
of non-tumor tissues. 
Western blotting. Total protein extracts were 
obtained after homogenization in RIPA lysis 
buffer (Santa Cruz Biotechnology). Nuclear 
extracts were prepared using the NE-PER 
nuclear and cytoplasmic extraction reagent kit 
(Pierce) and protein concentration was 
determined using a Pierce BCA protein assay kit. 
Primary antibodies were used at the following 
dilutions: rabbit polyclonal anti-L-FABP 1:2000 
(a gift of Dr. J Gordon), mouse monoclonals 
anti-FAS and anti-SREBP-1 (detecting both the 
SREBP-1a and SREBP-1c isoforms) 1:500 (BD 
Bioscience Pharmingen), polyclonals rabbit anti-
GK (Santa Cruz Biotechnology) and anti-ACL 
(Cell Signaling Technology) 1:200, polyclonal 
rabbit anti-ChREBP 1:1000 (Novus Biologicals). 
We used polyclonal rabbit anti-actin (1:3000, 
Sigma) and polyclonal rabbit anti-Lamin A/C 
(1:500, Cell Signaling Technology) as loading 
controls to normalize the signal obtained 
respectively for total and nuclear protein 
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extracts. Detection of signals was performed 
using the ECL SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) with either 
anti-mouse (1:4000, Amersham) or anti-rabbit 
(1:2000, Santa Cruz Biotechnology) horseradish 
peroxidase-conjugated IgG as second antibodies.  
Glucose-6-phosphate measurement. Glucose-6-
phosphate (G6P) concentrations were determined 
enzymatically in normal and tumor samples by 
exploiting the selective and quantitative 
conversion of G6P to 6-phosphogluconic acid in 
presence of NADP+ and G6PDH, as previously 
described (9).  
Histochemical analysis of glycogen storage. For 
this analysis, we used liver tissues frozen 
through immersion in isopentane cooled in liquid 
nitrogen. PAS histochemical staining was 
performed on frozen section from 5 HNF1α-
mutated HCA and 5 non-mutated HCA as well 
as their matched non-tumor livers.  
Lipid profiling. Detailed protocols used for lipid 
profiling are provided in the supplemental 
experimental procedures.  
Statistical analysis. All the values reported are 
mean ± SD. Statistical analysis was performed 
using GraphPad Prism version 4 software and 
significance was determined using the 
nonparametric Mann-Whitney test for unpaired 
data. Difference was considered significant at 
P<0.05.  
RESULTS 
Gene expression profiles in HNF1α-mutated 
HCA. Our cDNA and Affymetrix microarray 
experiments analyzed the expression of a total of 
15,000 different genes comparing respectively 8 
HNF1α-mutated HCA to their corresponding 
non-tumor liver and five HNF1α-mutated HCA 
to four non-tumor livers. Computational analysis 
of both experiments identified 375 and 222 
genes respectively significantly down and 
upregulated in HNF1α-mutated HCA. Among 
these genes, a large fraction was related to the 
normal hepatocyte function including 
carbohydrate and lipid metabolism, 
detoxification and synthesis of secreted proteins 
such as complement and coagulation factors 
(Supplemental Table 1). Among differentially 
expressed genes, promoter regions of 33 were 
previously identified to bound HNF1α in 
primary human hepatocytes using ChIP-on-chip 
technology (10). All but four of theses genes 
were downregulated in HNF1α-mutated HCA 
(Supplemental Table 1), which is in accordance 
with the well-known transactivating function of 
HNF1α. In addition, we identified 82 genes 
showing a common pattern of expression with 
liver from hnf1α-null mice (11) (Supplemental 
Table 1). Interestingly, 19 of these common 
deregulated genes were involved in glucido-
lipidic metabolism and particularly in bile acid 
metabolism, cholesterol and fatty acid synthesis 
(Supplemental Table 1).   
Fatty acid transport and oxidation. In HNF1α-
mutated HCA, we identified an important 
modification in the expression profiles of 
apolipoprotein genes. Particularly, components 
of the HDL particles encoded by APOM, LPAL2, 
APOF, LPA and APOA4 were strongly 
downregulated while APOL3 was upregulated 
(Supplemental Table 1). In contrast, the 
expression of critical genes for hepatocyte 
VLDL assembly and secretion such as APOB 
and MTP was not affected. We also found a 
dramatic decrease in the mRNA of FABP1 
encoding the liver fatty acid binding protein (L-
FABP). This result was confirmed by 
quantitative RT-PCR (-68-fold change, Figure 
1A) and by western-blotting analysis that 
showed an absence of L-FABP in mutated HCA 
(Figure 1B). In contrast, we did not find any 
change in the expression of genes encoding 
mitochondrial and peroxisomal β-oxidation 
enzymes. The expression level of genes encoding 
plasma membrane transporters such as CD36 
was also normal in mutated HCA as well as the 
LDL receptor gene. However, we identified a 
number of deregulated genes related to the 
lipogenesis pathway (Figures 2A and 3A).  
Gluconeogenesis repression and glycolysis 
activation. The expression of four genes (FBP1 
encoding the fructose-1,6-bisphosphatase, PCK1 
and PCK2 encoding respectively the cytosolic 
and the mitochondrial forms of the PEPCK 
enzyme and G6PT1 encoding the glucose-6-
phosphate transporter 1) critical to promote 
hepatic glucose production was significantly 
decreased in HNF1α-mutated HCA (Figure 2B), 
indicating a repression of the gluconeogenesis 
pathway in these tumors (Figure 2A). In contrast, 
glycolysis was activated in HNF1α-mutated 
HCA, since we found a strong upregulation of 
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glucokinase at the mRNA (GCK, 11-fold) and 
protein level (GK, Figure 2B and 2C). In 
addition, we found a 3-fold decrease in the 
expression of the GCKR transcript whose 
product acts as a negative regulator of 
glucokinase (Figure 2B). According to a 
predicted increased glucose phosphorylation rate, 
we showed a significantly higher level of 
glucose-6-phosphate in HNF1α-mutated HCA 
(Figure 2D). Moreover, PAS staining revealed a 
glycogen overload in these tumors consistent 
with G6P increase (Figure 2E). We also found an 
upregulation of GPI mRNA (4-fold, Figure 2B) 
which encodes the glucose phosphate isomerase, 
a second glycolytic enzyme. In contrast, PKLR 
mRNA which encodes the liver specific pyruvate 
kinase that catalyzes the last irreversible step of 
glycolysis was 3-fold decreased in HNF1α- 
mutated HCA (Figure 2F). However, PKLR 
downregulation may be balanced by a 2-fold 
increase of PKM2 gene that encodes the muscle 
specific pyruvate kinase (Figure 2F). 
Activation of the citrate shuttle. Besides the 
observed gluconeogenesis inhibition and 
glycolysis activation that predict an 
overproduction of pyruvate, a substrate for the 
mitochondrial synthesis of acetylCoA, the citrate 
shuttle system that export acetylCoA into the 
cytosol was also activated in HNF1α-mutated 
HCA (Figure 2A). Indeed, we found a 12-fold 
overexpression of ME1 mRNA which encodes 
the malic enzyme, a moderate 2-fold increase of 
MDH1 transcript and ACLY mRNA encoding the 
ATP citrate lyase (ACL) was 3.7-fold 
overexpressed in HNF1α-mutated HCA (Figure 
2B). As ATP citrate lyase is crucial to provide 
the unique cytoplasmic source of the acetylCoA 
lipogenic precursor, we confirmed by western-
blotting the ACL protein overexpression (Figure 
2C).  
Stimulation of the fatty acid synthetic pathway. 
As shown in Figure 3A, the fatty acid synthetic 
pathway was also stimulated in HNF1α-mutated 
HCA. We found an increase of the acetyl-CoA 
carboxylase transcript (ACACA, 2.6-fold) and a 
strong overexpression of fatty acid synthase at 
both trancriptional (FASN, 7-fold) and protein 
level (FAS, Figures 3B and 3C). In the 
downstream steps of fatty acid elongation and 
desaturation, we also identified an increase in the 
mRNA level of three genes encoding elongases 
including ELOVL1 (3.4-fold), ELOVL2 (2.2-
fold) and ELOVL5 (2.3-fold) and of three genes 
encoding desaturases such as SCD (6-fold), 
FADS1 (3-fold) and FADS2 (4.7-fold, Figure 
3B).  
Transcriptional alteration of glucido-lipidic 
genes defines an expression pattern that is 
specific of HNF1α-mutated HCA. To search if 
the pattern of alteration in the expression of the 
glucido-lipidic genes was specific of HNF1α 
inactivation, we compared the expression 
profiles of the 19 aforementioned genes between 
HNF1α-mutated HCA and a group of non-
mutated HCA containing or not steatosis, using 
quantitative RT-PCR. In this analysis, we also 
included steatotic non-tumor livers from 
different etiologies and non steatotic non-tumor 
livers. We then performed a non-supervised 
analysis of the results using a hierarchical 
clustering algorithm to group the genes as well 
as the samples on the basis of similarity in their 
expression pattern. This analysis accurately 
classified all samples in two major clusters 
according to their HNF1α status (Figure 4). 
Steatotic non-tumor livers and non-steatotic non-
tumor livers were gathered with the non-HNF1α-
mutated HCA. Gene cluster analysis identified 
two main groups corresponding to 
downregulated (cluster A) and upregulated 
(cluster B) genes in HNF1α-mutated HCA 
(Figure 4). As expected, four out of five genes 
identified in cluster A had been previously 
characterized as HNF1α transactivated targets. 
Interestingly, all upregulated genes have never 
been previously found regulated by HNF1α. 
Within cluster B, three subgroups of genes (1, 2, 
3) showed a highly correlated overexpression in 
HNF1α-mutated HCA (Supplemental Figure 1). 
For example, ACLY level of expression was 
correlated to ACACA overexpression in 16 
HNF1α-mutated HCA (Spearman r=0.72, 
P=0.001) (Supplemental Figure 1).  
In non-HNF1α-mutated liver tissues, only few 
genes demonstrated a significant transcriptional 
deregulation (Supplemental Figure 2). In 
steatotic non-tumor livers, expression of only 
two genes, PCK2 and ME1, followed an 
expression pattern as seen in HNF1α-mutated 
HCA (Supplemental Figure 2). In non-HNF1α-
mutated steatotic HCA, 9 genes involved in 
gluconeogenesis, glycolysis and citrate shuttle 
were significantly deregulated compared to the 
non-steatotic non-tumor livers (Supplemental 
Figure 2). One of these, GCK, showed an 
inversed pattern of deregulation when compared 
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to the HNF1α-mutated HCA. However, except a 
modest elevation in ELOVL1 transcript, 
expression of genes related to the fatty acid 
synthetic pathway were unchanged in this group 
of steatotic adenomas. Finally, in the group of 
non-HNF1α-mutated non-steatotic HCA only 
four genes showed a significant change in 
expression pattern (FBP1, GPI, ACLY, 
ELOVL1). 
These results indicated that patterns of 
expression of the 19 analyzed genes were 
specific to HNF1α inactivation. 
Downregulations could be directly attributed to 
the loss of the classical HNF1α transactivation 
activity. In contrast, overexpressed genes 
demonstrated a coordinated activation, but none 
are known to date to be directly controlled by 
HNF1α.  
Activation of lipogenesis in HNF1α-mutated 
HCA is independent of SREBP-1 and ChREBP 
activation. Among the lipogenic genes whose 
expression was increased in HNF1α-mutated 
HCA, 8 out of 13 were previously described as 
SREBP-1c targets. However, using quantitative 
RT-PCR, we did not find any significant 
variation in the mRNA level of total SREBP-1 in 
HNF1α-mutated HCA compared to non-tumor 
livers, nor in SREBP-1a (Figure 6A). Moreover, 
surprisingly, western-blotting studies revealed a 
decrease in the nuclear active form of SREBP-1 
in the tumors compared to their corresponding 
non-tumor liver (Figure 6B), and the microarray 
study also found an increase in INSIG1 (insulin 
induced gene 1) mRNA (2 fold, Supplemental 
Table 1) whose product is known to inhibit 
SREBP-1 cleavage processing. We then looked 
for a potential alteration of ChREBP expression, 
an other key transcriptional activator of fatty acid 
synthesis in the liver. RT-PCR results showed a 
significant decrease in the mRNA of CHREBP in 
HNF1α-mutated HCA (-1.8-fold, Figure 6A) and 
western blotting studies revealed a decrease of 
the protein level in the nucleus (Figure 6B). 
Using the same samples where we demonstrated 
a repression of both SREBP-1 and ChREBP, we 
found an obvious overexpression of the fatty 
acid synthase (FAS) and glucokinase (GK) 
proteins, which are known to be transactivated 
by these two transcription factors (Figure 6B). 
Although unexpected, these results suggest that 
increased lipogenic genes expression found in 
HNF1α-mutated HCA is not related to SREBP-1 
and ChREBP activation. FAS and GK 
overexpression were confirmed in three 
additional cases of HNF1α-mutated HCA 
(Supplemental Figure 3). In two of these three 
cases, ChREBP was decreased and the nuclear 
active form of SREBP-1 was highly reduced or 
unchanged. In the remaining case we found a 
mild elevation of ChREBP and nuclear SREBP-1 
compared to the non-tumoral counterpart. On the 
whole, we observed an increased expression of 
FAS and GK together with a clear repression of 
SREBP-1 and ChREBP in four out of 6 HNF1α-
mutated HCA analyzed. Interestingly, no similar 
pattern of expression was found in the non- 
HNF1α-mutated HCA tested (Supplemental 
Figure 3). We also checked for the 
transcriptional level of other transcription factors 
that have been implicated in the regulation of 
glucido-lipidic metabolism (Figure 6A). Except 
for a 1.9-fold elevation of PPARγ transcript, the 
mRNA level of FOXO1A, PPARα, LXRα and 
HNF4α  was not significantly different in 
HNF1α-mutated HCA compared to non-tumor 
livers (Figure 6A). Finally, the RXR isotypes 
genes were not differentially expressed in the 
microarray analysis. 
Total lipid composition is modified in HNF1α-
mutated HCA. We compared lipid profiles of 
four non-steatotic non-tumor livers with that of 
five HNF1α-mutated HCA. Total fatty acid 
content was 5.8-fold increased in HNF1α-
mutated HCA and the fatty acid profile was 
modified. Saturated (SFA) and monounsaturated 
(MUFA) fatty acids were 7- and 8-fold increased 
respectively, as a consequence of the 
accumulation of all SFA and MUFA species 
detected (Figure 3A, 5C and 5D). In contrast, 
polyunsaturated fatty acids (PUFA) were raised 
only 2-fold (Figure 5A) with a preferential 
accumulation of fatty acids containing 18 carbon 
atoms including the two essential fatty acids 
linoleic acid (18:2n-6) and α-linolenic acid 
(18:3n-3). Consequently, the SFA/PUFA and 
MUFA/PUFA ratios in mutated HCA were 
significantly higher than in non-tumor livers 
(Figure 5B). We also showed that C14-C18 fatty 
acids were much more increased than C20-C23 
fatty acids, as indicated by a 5-fold higher C14-
C18/C20-C23 ratio (Figure 5B). We also 
identified a mild elevation in free cholesterol 
content in HNF1α-mutated HCA (36 vs 26.2 
nmol/mg of proteins, Figure 5F), however, we 
did not find any change neither in total 
cholesterol esters and diglycerides contents 
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(Figure 5F) nor in specific molecular species 
related to these two neutral lipid classes (data not 
shown). In contrast, total and all species of 
triglycerides were dramatically increased in 
HNF1α-mutated HCA (Figures 5F and 5G). This 
overload was inversely proportional to the total 
number of carbon atoms of each species (ranging 
from a 53-fold for C49 to a 4.8-fold increase for 
C57 families, Figure 5G), according to the 
highest increase in C14-C16 fatty acid species 
versus C18-C20.  
Phospholipid profile is also changed in HNF1α-
mutated HCA. As shown in Table 1, HNF1α-
mutated HCA showed a 2-fold increase in total 
phospholipid quantity that was related to a 
significant elevation of phosphatidylcholine (PC) 
and phosphatidylethanolamine (PE), while 
content of the other phospholipid classes 
including sphingomyelin (SM) was unchanged 
compared to non-tumor livers (except for PS that 
was undetectable in the tumors). Our results also 
showed a significant elevation in the PE fraction 
whereas the PI fraction was reduced (Table 1), 
indicating that phospholipid profile was 
qualitatively changed. The fatty acid profile of 
PE was not significantly modified, while it was 
moderately alterated for PC and PS-PI classes 
(Table 2). In PS-PI, we found a significant 
elevation of the MUFA fraction (Table 2). In PC, 
the SFA and PUFA fractions were respectively 
decreased and increased, consequently, the PC-
unsaturation index was significantly increased in 
HNF1α-mutated HCA (Table 2). We also 
showed that C20-C24 were over-represented in 
the PC fraction of HNF1α-mutated HCA, as 
indicated by the significant decrease of the C16-
C18/C20-C24 ratio (1.8 fold). When analyzing 
fatty acid composition of the total phospholipids, 
we only found a reduction in the C16-C18/C20-
C24 ratio in HNF1α-mutated HCA (Table 2).  
DISCUSSION 
In the present work, careful analysis of 
the metabolic pathways alterated in the HNF1α-
mutated HCA may explain the severe fatty 
overload observed in these tumors. First, we 
identified a repression of gluconeogenesis 
coordinated with an activation of glycolysis and 
citrate shuttle predicting an aberrant 
accumulation of the acetylCoA and NADPH 
lipogenic precursors (12). In addition, these 
tumors also showed an obvious stimulation of 
the fatty acid synthetic pathway from palmitate 
synthesis to the downstream steps of fatty acid 
elongation and desaturation. Taken together, 
these findings provide evidence that de novo 
lipogenesis activity is increased in HNF1α-
mutated HCA, and we showed that it is 
specifically related to the loss of HNF1α 
activity. The fact that the steatotic non-HNF1α-
mutated HCA and the steatotic non-tumor livers 
did not show the same deregulated expression 
pattern as in mutated HCA suggests that lipid 
storage in these two groups of samples likely 
occurs independently of HNF1α inactivation. 
Moreover, since lipogenesis activity is known to 
be mainly regulated at the transcriptional level, it 
is unlikely that higher lipogenic rates would be a 
significant driver of fat accumulation in the 
steatotic non-HNF1α-mutated HCA or in the 
steatotic non-tumor livers. Indeed, in these two 
sample groups, no major transcriptional 
deregulation was found in the lipogenic pathway. 
However, it does not exclude a possible 
activation of lipogenesis at a post-transcriptional 
level. The importance of lipogenesis in human 
steatosis is still under discussion. Here, we report 
a particular situation in humans, in which 
hepatocyte steatosis developed in the context of 
HNF1α inactivation seems to be primarily due to 
an aberrant stimulation of lipogenic rate. 
In mice, loss of HNF1α activity was also 
associated with the development of fatty liver 
(13,14), and a prior work identified a significant 
elevation in the liver expression of the acetyl-
CoA carboxylase and fatty acid synthase genes 
(14). However, our study is the first one to 
demonstrate a coordinate overexpression of all 
lipogenic genes and to highlight the major 
involvement of this aberrant induction in the 
pathogenesis of fatty liver phenotype related to 
HNF1α inactivation. In the present work, we 
identified transcriptional deregulations of 19 
genes that may explain fat overload observed in 
the human HNF1α-mutated HCA. Interestingly, 
when extracting the expression data from the 
transciptome analysis performed by Shih et al. in 
the liver from hnf1α-null mice, we found that 9 
of theses 19 genes were commonly deregulated 
in mice. Moreover, it is remarkable that the most 
important overlap was found for the genes 
involved in the fatty acid synthetic pathway 
(5/9). 
Among the 19 deregulated genes, three 
of the 6 downregulated genes (FABP1, G6PT1 
and PCK1) were previously demonstrated to be 
directly transactivated by HNF1α and promoter 
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region of GCKR has been shown to bind HNF1α 
in vivo by ChIP (10,14-16). However, among the 
overexpressed genes, the majority were known to 
be transactivated by the membrane bound 
transcription factor SREBP-1c. SREBP-1c is 
considered as the master regulator of fatty acid 
synthesis in the liver, mediating effects of insulin 
on the expression of glycolytic and lipogenic 
genes after being activated by proteolytic 
cleavage (17). Surprisingly, in HNF1α-mutated 
HCA, SREBP-1 was repressed in most of the 
cases, possibly resulting from the induction of 
INSIG1 mRNA (18). This finding contrasts with 
that found in hnf1α-null mice liver in which a 
significant increase of SREBP-1 transcript was 
reported (11). ChREBP is an other transcription 
factor known to activate the expression of some 
lipogenic genes such as ACLY, ACACA, FASN 
(19). In HNF1α-mutated HCA we also found a 
reduction of the ChREBP mRNA level and 
nuclear protein amounts, demonstrating 
repression. This could occur as a consequence of 
the observed PUFA elevation in the tumors and 
particularly of the linoleic acid, that has been 
shown to suppress ChREBP activity by 
increasing its mRNA decay and altering its 
translocation from the cytosol to the nucleus 
(20). Thus, the repression of SREBP-1 and 
ChREBP observed in most of the analyzed 
HNF1α-mutated HCA could result from a 
negative feedback responding to lipid overload. 
Furthermore, although a large fraction of 
SREBP-1 targets were overexpressed in HNF1α-
mutated HCA, some well-known targets such as 
the 6-phosphogluconate dehydrogenase 
(6PGDH) and glucose-6-phosphate 
dehydrogenase (G6PDH), were not deregulated 
in mutated HCA. Altogether, our results imply 
that SREBP-1 and ChREBP are not responsible 
for the coordinate induction of glycolytic and 
lipogenic genes observed in HNF1α-mutated 
HCA. PPARγ was previously proposed to play a 
role in hepatic induction of lipogenic genes 
through a mechanism that is still unclear (21-23). 
In the HNF1α-mutated HCA, we found an 
increase in PPARγ gene expression, however, 
among three well-known targets of this 
transcription factor (FABP4, CD36 and UCP2) 
only one demonstrated a significant 
overexpression (FABP4 gene 5-fold, 
Supplemental Table 1) suggesting that PPARγ 
activity is not obviously increased in HNF1α-
mutated HCA. Thus, the mechanism by which 
HNF1α inactivation leads to the coordinate 
overexpression of the lipogenic genes remains to 
be elucidated. The strong correlation groups 
identified between overexpressed transcripts 
suggest that a transcriptional mechanism would 
be most likely at the origin of the observed 
deregulations, instead of a post-transcriptional 
regulation such as mRNA stability. 
Consequently, transcriptional activation of the 
lipogenic genes related to HNF1α inactivation 
may occur through the loss of a direct HNF1α 
repressor function involving either direct DNA 
binding or interaction with others transcription 
factors and co-activator proteins (Supplemental 
Figure 4A). Although, HNF1α has been mainly 
reported as a transcriptional activator, this model 
would explain some of the identified 
overexpressions. Indeed a co-repressor activity 
for HNF1α on its own transcription has already 
been shown through interaction with 
HNF4α (24). Alternatively, the absence of a 
functional HNF1α protein may also alter the 
expression of another transcription factor 
involved in the control of lipogenesis 
(Supplemental Figure 4B). New insights into 
understanding the mechanisms regulating 
lipogenic gene expression by HNF1α could 
come from the analysis of gene promoter activity 
in cellular systems in which HNF1α activity will 
be modulated. 
Results from lipid profiling analysis of 
the accumulated fat in HNF1α-mutated HCA are 
well correlated with the transcriptional 
deregulations observed in the fatty acid synthetic 
pathway. Indeed, the preferential accumulation 
of SFA and MUFA species is in accordance with 
the strong overexpression of FAS and SCD, and 
with the high elevation of ELOVL1 expression 
(25-27). The significant accumulation of the two 
essential fatty acids linoleic acid and α-linolenic 
acid suggests that in addition to the elevated 
rates of lipogenesis, other mechanisms may 
contribute to the fatty phenotype in HNF1α-
mutated HCA. This is unlikely the consequence 
of impaired VLDL secretion or fatty acid entry 
into the tumor hepatocytes, since no obvious 
deregulations in the expression of the genes 
involved in these processes was identified. 
However, although expression of fatty acid 
oxidation genes was unchanged in HNF1α-
mutated HCA, it is likely that fatty acid 
oxidation is reduced in adenoma cells secondary 
to lipogenic rate increase. Indeed, this may occur 
through the inhibition of CPT1 activity resulting 
from the overproduction of malonyl-CoA by the 
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acetylCoA carboxylase whose transcript was 
significantly upregulated in HNF1α-mutated 
HCA. Thus, a secondary defect in β-oxidation 
may contribute to fat accumulation and may 
explain in part the observed elevation of essential 
fatty acids. Moreover, given the role of L-FABP 
in binding, trafficking and compartmentalization 
of fatty acids into the hepatocyte, the dramatic 
decrease in L-FABP expression may also 
participate to the steatotic phenotype, as 
suggested in hnf1α-null mice liver (28). The 
alteration of phospholipid profile in HNF1α-
mutated HCA was moderate. However, it may 
cause deregulation of membrane functioning in 
adenoma cells leading to alteration of critical 
cellular processes related to tumorigenesis.  
In this study, we clearly demonstrated 
that lipogenesis activity was increased in 
HNF1α-mutated HCA and this feature has been 
commonly observed in tumor cells. Indeed, 
overexpression of the fatty acid synthase was 
previously identified in a wide variety of cancers 
as well as in precancerous lesions (29). This 
overexpression was often accompanied by a 
coordinate induction of the other lipogenic 
enzymes and several studies have shown that 
tumor cell survival may depend on de novo 
synthesis of fatty acids. While the fatty acid 
synthase as been proposed as an interesting 
therapeutic target for cancer treatment, more 
recent studies showed that the inhibition of other 
lipogenic enzymes like acetylCoA carboxylase 
or ATP citrate lyase can also limit cancer cell 
proliferation and survival (30,31). Recently, we 
proposed HNF1α as a tumor suppressor gene (3) 
and we demonstrated in the present work, that 
lipogenesis activation in HNF1α-mutated HCA 
results from the loss of HNF1α activity. This 
finding may contribute to reinforce the emerging 
concept that induction of lipogenesis observed in 
tumor cells would occur downstream from 
oncogenic events (29) and open new avenues to 
understand how metabolism deregulations may 
contribute to benign liver tumorigenesis. Finally, 
our findings have potential clinical implications 
since lipogenesis can be efficiently inhibited by 
targeted therapies. 
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 ABBREVIATIONS 
ACACA, acetyl-CoA carboxylase-alpha; ACLY/ACL, ATP citrate lyase; CE, cholesterol esters; ChIP, 
chromatin immunoprecipitation; ChREBP, carbohydrate response element binding protein; DG, 
diglycerides; ELOVL1, elongation of very long chain fatty acids protein 1; ELOVL2, elongation of 
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very long chain fatty acids protein 2; ELOVL5, ELOVL family member 5, elongation of very long 
chain fatty acids; FA, fatty acids; FABP1/L-FABP, liver fatty acid binding protein; FADS1, fatty acid 
desaturase 1; FADS2, fatty acid desaturase 2; FASN/FAS, fatty acid synthase; FBP1, fructose-1,6-
bisphosphatase; FOXO1A, forkhead box O1A; GCK/GK, glucokinase; GCKR, glucokinase regulatory 
protein; G6P, glucose-6-phosphate; GPI, glucose-6-phosphate isomerase; G6PT1, glucose-6-
phosphate transporter 1; HCA, hepatocellular adenoma; HNF1α, hepatocyte nuclear factor 1-α; 
HNF4α, hepatocyte nuclear factor 4- alpha; INSIG1, insulin induced gene 1; LXRα, liver X receptor, 
alpha; ME1, malic enzyme 1; MODY3, maturity onset diabetes of the young type 3; MDH1, NADPH 
malate dehydrogenase, soluble; MUFA, monounsaturated fatty acids; PC, phosphatidylcholine; PCK1, 
phosphenolpyruvate carboxykinase 1, soluble; PCK2, phosphenolpyruvate carboxykinase 2, 
mithochondrial; PE, phosphatidylethanolamine; PKLR, pyruvate kinase, liver and red blood cell; 
PKM2, pyruvate kinase muscle 2; PL, phospholipids; PPARα, peroxisome proliferator-activated 
receptor-alpha; PPARγ, peroxisome proliferator-activated receptor-gamma; PS-PI, 
phosphatidylserine-phosphatidylinositol; PUFA, polyunsaturated fatty acids; SCD, stearoyl-CoA 
desaturase; SFA, saturated fatty acids; SM, sphingomyelin; SREBP-1, sterol regulatory element-
binding protein-1; TCF1, transcription factor 1; TG, triglycerides; UFA, unsaturated fatty acids; UI, 
unsaturation index  
FIGURES LEGENDS 
Fig. 1. Expression of FABP1 transcript and L-FABP protein in HNF1α-mutated HCA. 
A. mRNA level of FABP1 gene was assessed using quantitative RT-PCR. Results are expressed as the 
n-fold difference in gene expression relative to the mean expression value of non-tumor livers. Data 
are mean ± SD. *** difference between groups at P<0.001. B. Protein level of L-FABP (14 kDa) was 
compared between 3 HNF1α-mutated HCA (T1, T2, T3) and their respective corresponding non-tumor 
liver (N1, N2, N3) using western-blotting. β-actin was used as loading control. 
Fig. 2. Gluconeogenesis repression, glycolysis and citrate shuttle activation in HNF1α-
mutated HCA. A. Schematic representation of gluconeogenic pathway (gray arrows), glycolytic 
pathway and citrate shuttle (black arrows). Dashed arrows indicate several reaction steps. Genes 
whose expression was deregulated in HNF1α-mutated HCA are in solid boxes. (½) and (¾) indicate 
transcripts that are respectively upregulated and downregulated compared to non-tumor livers. * 
indicates a significant increase in the product quantity. B. Quantitative RT-PCR validation of gene 
array expression data. Results are expressed as the n-fold difference in gene expression relative to the 
mean expression value of non-tumor livers. Data are mean ± SD. *, **, *** difference between groups 
at P<0.05; 0.01 and 0.001 respectively. C. Protein level of GK (52 kDa) and ACL (125 kDa) was 
compared by western-blotting analysis between 2 HNF1α-mutated HCA (T1, T2) and their respective 
corresponding non-tumor liver (N1, N2). β-actin was used as loading control. D. G6P content 
measurement. Values are mean ± SD. ** difference between groups at P<0.01. E. Frozen sections of a 
non-HNF1α-mutated HCA (a) and an HNF1α-mutated HCA (b). Glycogen storage in cytoplasm of 
hepatocytes (red color with PAS staining) is increased in HNF1α-mutated HCA (b) compared with 
non-mutated HCA (a). F. mRNA level of PKLR and PKM2 genes was assessed using quantitative RT-
PCR. Results are expressed as the n-fold difference in gene expression relative to the mean expression 
value of non-tumor livers. Data are mean ± SD. *** difference between groups at P<0.001 
Fig. 3. Activation of the fatty acid synthetic pathway in HNF1α-mutated HCA. A. 
Schematic representation of the fatty acid synthetic pathway. Dashed arrows indicate several reaction 
steps that occur only in plants. Genes whose expression was deregulated in HNF1α-mutated HCA are 
in solid boxes. (½) indicates transcript upregulation compared to non-tumor livers. * indicates fatty 
acid species significantly raised in HNF1α-mutated HCA compared to non-tumor livers, FA: fatty 
acids. B. Quantitative RT-PCR validation of gene array expression data. Results are expressed as the 
n-fold difference in gene expression relative to the mean expression value of non-tumor livers. Data 
are mean ± SD. **, ***, difference between groups at P<0.01 and 0.001 respectively. C. Protein level 
 10
H
AL author m
anuscript    inserm
-00138278, version 1
H
AL author m
anuscript    inserm
-00138278, version 1
HNF1α inactivation promotes hepatic lipogenesis                                                                                                               
of FAS (265 kDa) was compared by western-blotting analysis between 2 HNF1α-mutated HCA (T1, 
T2) and their respective corresponding non-tumor liver (N1, N2). β-actin was used as loading control. 
Fig. 4. Unsupervised hierarchical clustering of the 19 genes differentially expressed in 
HNF1α-mutated HCA that are related to their steatotic phenotype. The dendrogram was obtained 
based on the expression profile of quantitative RT-PCR data. Samples and genes were classified using 
the dChip 1.3 software and Pearson correlation algorithm. The data are shown in a table format in 
which rows represent individual gene and columns represent individual tissue. Red and green colors 
indicate transcript expression levels respectively above and below the mean (black) expression value 
for each gene across the entire set of tissue samples. 
Fig. 5. Quantification of total fatty acids and neutral lipids. All the results are expressed as 
mean ± SD. * difference between groups at P<0.05. A. Total fatty acids (FA) content. B. Ratio of total 
fatty acids. C. SFA quantification. D. MUFA quantification. E. PUFA quantification. F. 
Quantification of neutral lipids classes, CE: cholesterol esters, DG: diglycerides, TG: triglycerides . G. 
Measurement of triglyceride families defined according to their total number of carbon atoms. 
Fig. 6. Expression of transcription factors involved in the regulation of liver glucido-
lipidic metabolism. A. mRNA level was assessed using quantitative RT-PCR. Results are expressed 
as the n-fold difference in gene expression relative to the mean expression value of non-tumor livers. 
Data are mean ± SD. *, **, *** difference between groups at P<0.05, 0.01, and 0.001 respectively. B. 
Protein level of SREBP-1 (precursor form 125 kDa and mature form 68 kDa) and ChREBP (95 kDa) 
were analysed by western-blotting in total and nuclear protein fraction from 3 HNF1α-mutated HCA 
(T1, T2, T3) and their respective corresponding non-tumor liver (N1, N2, N3) ; the expression level of 
FAS (265 kDa) and GK (52 kDa) proteins, two targets of SREBP-1 and ChREBP was also assessed in 
the total protein fraction from the same samples. β-actin and Lamin A/C were used as loading controls 
for total and nuclear extracts respectively.  
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Table 1. Quantification of phospholipid classes. 
Non-tumor liversa HNF1α-mutated HCAb Non-tumor livers HNF1α-mutated HCA
Total PL 392.13 ± 75.35 868.38 ± 234.67***
PC 215.55 ± 57.87 418.92 ± 98.32*** 55.21 ± 10.84 48.68 ± 4.06
PE 131.26 ± 41.33 385.76 ± 119*** 33.07 ± 9.78 44.23 ± 4.64*
PI 18.44 ± 4.66 29.92 ± 15.41 4.74 ± 0.93 3.32 ± 1.07*
PS 3.5 ± 6.49 nd 0.97 ± 1.8 nd
SM 23.18 ± 12.4 33.89 ± 25.52 6.01 ± 3.2 3.77 ± 2.88
(pmol/mg of protein) (% of total phospholipids)
 % of  total fatty 
acids
Non-tumor 
liversa 
HNF1α- 
mutated HCAb 
Non-tumo
li ers 
                Total PL                     PC                     PE                   PS-PI
r 
v
HNF1α-  
mutated HCA 
Non-tumor 
livers 
HNF1α- 
mutated HCA 
Non-tumor 
livers 
HNF1α-  
mutated HCA
 1.12 47.34 ± 3.26 54.15 ± 4.36 56.08 ± 3.07
75 8.16 ± 1.81 7.66 ± 0.95 11.99 ± 0.68*
SFA 49.13 ± 1.18 46.61 ± 1.75 47.96 ± 1.7 44.66 ± 0.99* 48.96 ±
MUFA 10.71 ± 1.39 10.31 ± 1.41 13.33 ± 2.01 11.48 ± 1.75 7.84 ± 0.
PUFA 40.16 ± 1.96 43.08 ± 1.97 38.71 ± 2.3 43.86 ± 2.19* 43.2 ± 1.6 44.5 ± 3.17 38.19 ± 5 31.93 ± 2.57
MUFA/PUFA 0.27 ± 0.04 0.24 ± 0.04 0.35 ± 0.07 0.26 ± 0.05 0.18 ± 0.02 0.18 ± 0.04 0.21 ± 0.05 0.38 ± 0.02*
MUFA/SFA 0.22 ± 0.03 0.22 ± 0.03 0.28 ± 0.05 0.26 ± 0.04 0.16 ± 0.01 0.17 ± 0.05 0.14 ± 0.01 0.21 ± 0.02*
SFA/PUFA 1.23 ± 0.08 1.08 ± 0.09 1.24 ± 0.10 1.02 ± 0.07* 1.14 ± 0.07 1.07 ± 0.15 1.45 ± 0.32 1.77 ± 0.25
SFA/UFA 0.97 ± 0.05 0.87 ± 0.06 0.92 ± 0.06 0.81 ± 0.03* 0.96 ± 0.04 0.90 ± 0.12 1.20 ± 0.22 1.29 ± 0.17
C14-C18/C20-C24 3.11 ± 0.49 2.18 ± 0.28* 5.26 ± 1.04 2.87 ± 0.46* 1.85 ± 0.29 1.48 ± 0.2 2.42 ± 0.59 2.46 ± 0.4
UI 1.48 ± 0.11 1.70 ± 0.12 1.27 ± 0.10 1.55 ± 0.08* 1.81 ± 0.11 1.97 ± 0.22 1.46 ± 0.21 1.40 ± 0.11
 
 
 
PL: phospholipids. Values are mean ± SD. nd: not detected. *, *** difference between groups at 
P<0.05 and 0.001 respectively. an=8, bn=8 
Table 2. Fatty acid composition in each class of phospholipid.  
 
Values are mean ± SD. UI, Unsaturation index=Σ (% each unsaturated fatty acid x number of double 
bonds of the same fatty acid)/100. * difference between groups at P<0.05. an=4, bn=5 
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Figure 4 
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Figure 5 
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Figure 6 
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SUPPLEMENTAL DATA 
Supplemental experimental procedures 
Microarray analysis. In a first experiment, expression patterns were compared between 8 HNF1α-
mutated HCA and their corresponding non-tumor livers using cDNA in-house manufactured arrays 
previously described (1). Briefly, one microgram of each amplified RNA and human universal 
reference RNA (Stratagene) were labeled alternatively with Cy5-dCTP and Cy3-dCTP and co-
hybridized onto glass array slides containing 11,250 cDNA spotted sequences. We carried out two 
hybridizations for each tissue using a dye-swap strategy. Primary data collection, filtering and 
normalization of gene expression were done as described in Graudens et al, (1). 
In the second experiment, we used HG-U133A Affymetrix GeneChipTM arrays to compare the 
expression profiles of 5 HNF1α-mutated HCA and 4 non-related non-tumor livers analysing the 
expression level of 19,787 probe sets.  
Statistical analysis of both cDNA and Affymetrix GeneChip arrays data was performed using 
multiple testing procedures to evaluate statistical significance for differentially expressed genes, as 
previously described (1). Two gene selection methods were applied (i) significance analysis of 
microarrays [SAM; (2)], and (ii) p-value ranking using z-statistics in ArrayStat 1.0 software (Imaging 
Research Inc.), t-statistics via the dChip program and the class comparison tools available in BRB-
ArrayTools v3.2.3 package, an Excel Add-in (3). Statistical tests were computed for each probe set 
using the log-transformed data and a probe set was declared to be significant when the p-value was 
less than the α-level=0.001. For multiple testing corrections, the false discovery rate (FDR) procedure 
was used (4). Univariate and multivariate permutation tests (n>1000) were computed to control the 
proportion of false discoveries (i.e. false positives, > 90% confidence) in the “discovery list”. To 
assess the classification accuracy, a variety of methods were used in BRB-ArrayTools v3.2.3 package, 
including unsupervised compound covariate, diagonal linear discriminant analysis, k-nearest-neighbor 
(k=1 and 3), nearest centroid, and support vector machine predictors. For all of those class prediction 
methods, the cross-validated misclassification rate was calculated using the leave-one-out voting 
classifier validation (α-level=0.001).  
Lipid profiling. Following homogenization of tissue samples in methanol/ 5mM EGTA (2:1 v/v), 
lipids corresponding to an equivalent of 1 mg of tissue were extracted according to Bligh and Dyer (5) 
in chloroform/methanol/water (2.5 :2.5 :2.1, v/v/v), in the presence of the internal standards : 6 μg of 
stigmasterol, 4 μg of 1,3-dimyristine, 4 μg of cholesteryl heptadecanoate and 6 μg of glyceryl 
triheptadecanoate. Neutral lipids were analyzed by gas-liquid chromatography on a FOCUS Thermo 
Electron system using a Zebron-1 Phenomenex fused silica capillary columns (5m X 0,32mm i.d, 0.50 
mm film thickness) (6). Oven temperature was programmed from 200°C to 350°C at a rate of 5°C per 
min and the carrier gas was hydrogen (0.5 bar). The injector and the detector were at 315°C and 345°C 
respectively.  
To measure total fatty acid methyl ester molecular species (FAME), lipids corresponding to an 
equivalent of 1mg of liver were extracted in the presence of glyceryl triheptadecanoate (0.5μg) as an 
internal standard. The lipid extract was transmethylated with 1ml of acetyl chloride in methanol (1 /20, 
v/v) for 90 min at 55°C, evaporated to dryness and the FAMEs were extracted with hexane/water 1:1. 
The organic phase was evaporated to dryness and dissolved in 50μl ethyl acetate. 1μl of FAME was 
analyzed by gas-liquid chromatography (7) on a 5890 Hewlett Packard system using a Famewax 
RESTEK fused silica capillary columns (30 m x 0.32 mm i.d, 0.25 mm film thickness). Oven 
temperature was programmed from 110°C to 220°C at a rate of 2°C per min and the carrier gas was 
hydrogen (0.5 bar). The injector and the detector were at 225°C and 245°C respectively.  
Measurement of fatty acid methyl ester molecular species of phospholipids was performed 
using lipid extract corresponding to an equivalent of 5 mg of liver. Phospholipids were separated by 
Thin Layer Chromatography in chloroform:methanol:water:acetic acid (65:43:3:1). Standards were 
run in parallel, stained with iodine and phospholipids spots were identified, scrapped and eluted three 
times with 1ml of chloroform:methanol (2:1). Extracts from PC, PS-PI and PE were evaporated to 
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dryness and transmethylated in the presence of nonadecanoic acid (2 μg). FAMEs were extracted in 
hexane, re-dissolved in 20μl of ethyl acetate and analysed as above. 
To measure phospholipid classes, lipids corresponding to an equivalent of 2 mg of liver were 
extracted. The lipid extract was dissolved in 40 μl of chloroform and 20μl was analysed by HPLC on a 
Summit DIONEX system using a Uptisphere 6OH (5μm) 250 X 2mm column. The flow rate was 0.2 
ml/min and the column temperature was kept at 35°C during all runs. A light-scattering detector was 
used for the detection (Polymer Laboratories PL-ELS2100). The evaporator and nebulisator 
temperature was 80°C, and nitrogen pressure was 1.2 ml/min. A ternary solvent system was used: A, 
isopropanol; B, hexane; C, water. Triethylamine (0.08%, v/v) and acetic acid (1%, v/v) were added to 
the solvents. The column was equilibrated in 60% B and 2% C and the sample was injected Then the 
gradient was moved to 49% B and 5,6% C in 23 min and to 0% B and 14% C in 7 min. Finally the 
gradient was returned to the starting conditions in 10 min and the column was equilibrated for 45min 
before next run. 
1. Graudens, E., Boulanger, V., Mollard, C., Mariage-Samson, R., Barlet, X., Gremy, G., 
Couillault, C., Lajemi, M., Piatier-Tonneau, D., Zaborski, P., Eveno, E., Auffray, C., and 
Imbeaud, S. (2006) Genome Biol 7(3), R19 
2. Tusher, V. G., Tibshirani, R., and Chu, G. (2001) Proc Natl Acad Sci U S A 98(9), 5116-5121 
3. Korn, E. L., McShane, L. M., Troendle, J. F., Rosenwald, A., and Simon, R. (2002) Br J 
Cancer 86(7), 1093-1096 
4. Benjamini, Y., and Hochberg, Y. (1995) J Roy Stat Soc Series B-Methodological 57, 289-300 
5. Bligh, E. G., and Dyer, W. J. (1959) Can J Biochem Physiol 37(8), 911-917 
6. Barrans, A., Collet, X., Barbaras, R., Jaspard, B., Manent, J., Vieu, C., Chap, H., and Perret, 
B. (1994) J Biol Chem 269(15), 11572-11577 
7. Lillington, J. M., Trafford, D. J., and Makin, H. L. (1981) Clin Chim Acta 111(1), 91-98 
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Supplemental Tables and Figures  
Supplemental Fig 1. Correlations between overexpressed transcripts of the lipogenesis 
pathway identified in HNF1α-mutated HCA. A. Correlations for each upregulated transcript versus 
the other indicated upregulated transcripts were assessed by Spearman's rank correlation test using the 
quantitative RT-PCR data obtained in the group of HNF1α-mutated HCA. *, **, *** difference 
between groups at P<0.05, 0.01, and 0.001 respectively (significant correlations are highlighted in 
black). ns: correlation is not significant. B. Example of graphical representation of significant 
correlations identified between FASN, ACLY and ACACA transcripts, three key genes of the 
lipogenesis pathway.  
Supplemental Fig 2. Expression of the 19 differentially expressed genes that may explain 
steatosis in HNF1α-mutated HCA, in other subtypes of liver tissues with or without steatosis. 
mRNA level was assessed using quantitative RT-PCR. For each group of samples, results are 
expressed as the n-fold difference in gene expression relative to the mean expression value of non-
steatotic non-tumor livers. Data are mean ± SD. *, **, *** difference between groups at P<0.05, 0.01, 
and 0.001 respectively. 
Supplemental Fig 3. Expression of SREBP-1, ChREBP, FAS and GK proteins in 
HNF1α-mutated HCA and in non-HNF1α-mutated non-steatotic HCA. SREBP-1 (precursor form 
125 kDa and mature form 68 kDa) and ChREBP (95 kDa) expression was analyzed by western-
blotting in total and nuclear protein fraction from three additional cases of HNF1α-mutated HCA (T4, 
T5, T6) and their respective corresponding non-tumor liver (N4, N5, N6), as well as in three non-
HNF1α-mutated non-steatotic HCA (T7, T8, T9) and their respective corresponding non-tumor liver 
(N7, N8, N9). The expression level of FAS (265 kDa) and GK (52 kDa) proteins, two targets of 
SREBP-1 and ChREBP was also assessed in the total protein fraction from the same samples. β-actin 
and Lamin A/C were used as loading controls for total and nuclear extracts respectively.  
Supplemental Fig 4. Model of the hypothetical mechanisms by which HNF1α may 
control lipogenic gene expression. A. Direct mechanism: HNF1α may act as a direct repressor of 
lipogenic genes promoter activity, through direct DNA binding or by interacting with an unknown 
activator transcription factor or co-activator proteins (A). B. Indirect mechanism: 1) HNF1α may 
activate the transcription of a repressor protein (R) involved in the promoter repression of lipogenic 
genes 2) HNF1α may repress the expression of an activator protein (A) involved in the transcriptional 
activation of the lipogenic genes expression. 
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Fold change T/N Genes commonly 
deregulated in 
hnf1α - null mice
Genes commonly 
deregulated in hnf1α -null 
mice related to glucido-
lipidic metabolism
ChIP 
Odom et 
al. , 2004Ensembl Gene ID Gene Symbol Gene Name cDNA Affymetrix
ENSG00000167910 CYP7A1 Cytochrome P450, family 7, subfamily A, polypeptide 1 17,6 + bile acid synthesis
ENSG00000084453 SLCO1A2
Solute carrier organic anion 
transporter family, member 
1A2
4,5 + bile acid transporter
ENSG00000104549 SQLE Squalene epoxidase 4,3 + cholesterol synthesis
ENSG00000113161 HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 2,7 + cholesterol synthesis
ENSG00000160285 LSS
Lanosterol synthase (2,3-
oxidosqualene-lanosterol 
cyclase)
2,0 + cholesterol synthesis
ENSG00000065833 ME1 Malic enzyme 1, NADP(+)-dependent, cytosolic 5,9 + citrate shuttle
ENSG00000134824 FADS2 Fatty acid desaturase 2 3,3 + fatty acid synthesis
ENSG00000169710 FASN Fatty acid synthase 2,3 3,0 + fatty acid synthesis
ENSG00000197977 ELOVL2
Elongation of very long chain 
fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 2
2,5 + fatty acid synthesis
ENSG00000099194 SCD Stearoyl-CoA desaturase (delta-9-desaturase) 2,1 + fatty acid synthesis
ENSG00000170323 FABP4 Fatty acid binding protein 4, adipocyte 5,3 + fatty acid traffiking
ENSG00000105220 GPI Glucose phosphate isomerase 1,8 2,1 + glycolysis
ENSG00000111666 CHPT1 Choline phosphotransferase 1 1,9 + phospholipid synthesis
ENSG00000137700 SLC37A4
Solute carrier family 37 
(glycerol-6-phosphate 
transporter), member 4
-2,7 -3,8 + gluconeogenesis
ENSG00000166035 LIPC Lipase, hepatic -9,4 + lipoprotein catabolism
ENSG00000111964 APOM Apolipoprotein M -22,8 + lipoprotein metabolism
ENSG00000163586 FABP1 Fatty acid binding protein 1, liver -500,0 + fatty acid traffiking
ENSG00000111700 SLCO1B3
Solute carrier organic anion 
transporter family, member 
1B3
-87,6 + bile acid transporter
ENSG00000131910 NR0B2 Nuclear receptor subfamily 0, group B, member 2 -2,4 + bile acid metabolism x
ENSG00000113600 C9 Complement component 9 -1000,0 +
ENSG00000132693 CRP C-reactive protein, pentraxin-related -4,3 -666,7 + x
ENSG00000165841 CYP2C19 Cytochrome P450, family 2, subfamily C, polypeptide 19 -126,9 +
ENSG00000145826 LECT2 Leukocyte cell-derived chemotaxin 2 -55,6 +
ENSG00000126838 PZP Pregnancy-zone protein -38,5 + x
ENSG00000148702 HABP2 Hyaluronan binding protein 2 -26,5 + x
ENSG00000130649 CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 -26,3 +
ENSG00000168679 SLC16A4
Solute carrier family 16 
(monocarboxylic acid 
transporters), member 4
-1,5 -15,3 +
ENSG00000132703 APCS Amyloid P component, serum -4,6 -14,3 + x
ENSG00000160932 LY6E Lymphocyte antigen 6 complex, locus E -12,3 + x
ENSG00000196083 IL1RAP Interleukin 1 receptor accessory protein -10,8 +
Supplemental Table 1. Results from cDNA and Affymetrix microarray experiments comparing respectively 8 HNF1α-
mutated HCA to their matched non-tumor livers (N), and five HNF1α-mutated HCA to four non-related non-tumor livers. 
Data are expressed as the n-fold difference in gene expression in HNF1α-mutated HCA (T) relative to non-tumor livers (N). Genes 
commonly deregulated in hnf1 α -null mice (+) includes primarily data extracted from the transcriptional profiling analysis 
performed by Shih et al.  in the liver from hnf1 α -null mice and others previous candidate gene approach studies, red and green 
colors indicate respectively genes whose expression was found upregulated and downregulated in the liver from hnf1 α -null mice. 
(x) indicates genes whose promoter region was previously identified by Odom et al.  to bind HNF1α in primary human hepatocytes, 
using ChIP.
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ENSG00000065154 OAT Ornithine aminotransferase (gyrate atrophy) -10,8 +
ENSG00000112299 VNN1 Vanin 1 -10,5 +
ENSG00000164825 DEFB1 Defensin, beta 1 -10,3 +
ENSG00000055957 ITIH1 Inter-alpha (globulin) inhibitor H1 -9,5 +
ENSG00000079557 AFM Afamin -9,0 +
ENSG00000185187 SIGIRR Single Ig IL-1R-related molecule -3,6 -8,9 +
ENSG00000149124 GLYAT Glycine-N-acyltransferase -4,1 -8,7  + 
ENSG00000116791 CRYZ Crystallin, zeta (quinone reductase) -8,4 +
ENSG00000170099 SERPINA6
Serine (or cysteine) proteinase 
inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), 
member 6
-8,2 + x
ENSG00000140505 CYP1A2 Cytochrome P450, family 1, subfamily A, polypeptide 2 -7,8 +
ENSG00000135220 FLJ21934 Hypothetical protein FLJ21934 -6,5 + x
ENSG00000138115 CYP2C8 Cytochrome P450, family 2, subfamily C, polypeptide 8 -2,7 -5,4 +
ENSG00000154153 FLJ20152 Hypothetical protein FLJ20152 -5,2 +
ENSG00000021488 SLC7A9
Solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 9
-4,5 +
ENSG00000143278 F13B Coagulation factor XIII, B polypeptide -4,3 +
ENSG00000104870 FCGRT Fc fragment of IgG, receptor, transporter, alpha -4,2 +
ENSG00000181784 RNASE4 Angiogenin, ribonuclease, RNase A family, 5 -1,8 -4,1 +
ENSG00000170095 GK Glycerol kinase -3,7 +
ENSG00000117594 HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 -3,7 + x
ENSG00000136960 ENPP2
Ectonucleotide 
pyrophosphatase/phosphodies
terase 2 (autotaxin)
-3,5 +
ENSG00000151790 TDO2 Tryptophan 2,3-dioxygenase -3,7 -3,5 +
ENSG00000080166 DCT
Dopachrome tautomerase 
(dopachrome delta-isomerase, 
tyrosine-related protein 2)
-3,5 +
ENSG00000170095 GKP3 Glycerol kinase pseudogene 3 -3,3 +
ENSG00000115290 GRB14 Growth factor receptor-bound protein 14 -3,2 +
ENSG00000086696 HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 -1,8 -3,1 + x
ENSG00000120833 SOCS2 Suppressor of cytokine signaling 2 -1,7 -2,8 +
ENSG00000118514 ALDH8A1 Aldehyde dehydrogenase 8 family, member A1 -2,8 +
ENSG00000160282 FTCD Formiminotransferase cyclodeaminase -2,7 +
ENSG00000132541 HRSP12 Heat-responsive protein 12 -2,6 +
ENSG00000171759 PAH Phenylalanine hydroxylase -2,6 +
ENSG00000188313 PLSCR1 Phospholipid scramblase 1 -2,5 +
ENSG00000144035 CML2 Putative N-acetyltransferase Camello 2 -2,4 +
ENSG00000017427 IGF1 Insulin-like growth factor 1 (somatomedin C) -2,2 -2,4 +
ENSG00000107554 DNMBP Dynamin binding protein -2,3 +
ENSG00000139547 RODH-4 Microsomal NAD+-dependent retinol dehydrogenase 4 -2,2 +
ENSG00000112964 GHR Growth hormone receptor -2,2 +
ENSG00000172828 FLJ21736 Esterase 31 -2,2 +
ENSG00000015475 BID BH3 interacting domain death agonist -1,3 -2,2 +
ENSG00000122194 PLG Plasminogen -2,0 + x
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ENSG00000118271 TTR Transthyretin (prealbumin, amyloidosis type I) -1,8 +
ENSG00000176890 TYMS Thymidylate synthetase 1,6 1,8 +
ENSG00000146701 MDH2 Malate dehydrogenase 2, NAD (mitochondrial) 1,3 1,9 +
ENSG00000197448 GSTK1 Glutathione S-transferase kappa 1 1,9 +
ENSG00000164089 AGXT2L1 Alanine-glyoxylate aminotransferase 2-like 1 1,9 +
ENSG00000135002 RFK Riboflavin kinase 2,0 +
ENSG00000169903 TM4SF4 Transmembrane 4 L six family member 4 2,1 + x
ENSG00000198638 HLA-B Major histocompatibility complex, class I, B 2,3 +
ENSG00000112186 CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast) 1,4 2,7 +
ENSG00000187837 HIST1H1C Histone 1, H1c 2,1 2,7 +
ENSG00000124107 SLPI Secretory leukocyte protease inhibitor (antileukoproteinase) 3,2 + x
ENSG00000182718 ANXA2 Annexin A2 1,6 3,4 +
ENSG00000169245 CXCL10 Chemokine (C-X-C motif) ligand 10 4,0 +
ENSG00000075142 SRI Sorcin 2,0 x
ENSG00000106105 GARS Glycyl-tRNA synthetase 2,2 x
ENSG00000151632 AKR1C2
Aldo-keto reductase family 1, 
member C2 (dihydrodiol 
dehydrogenase 2; bile acid 
binding protein; 3-alpha 
hydroxysteroid 
dehydrogenase, type III)
-1,9 x
ENSG00000137106 GRHPR
Glyoxylate 
reductase/hydroxypyruvate 
reductase
-1,6 -2,0 x
ENSG00000166825 ANPEP
Alanyl (membrane) 
aminopeptidase 
(aminopeptidase N, 
aminopeptidase M, 
microsomal aminopeptidase, 
CD13, p150)
-2,5 x
ENSG00000084734 GCKR Glucokinase (hexokinase 4) regulator -3,7 x
ENSG00000165272 AQP3 Aquaporin 3 -3,8 x
ENSG00000198610 AKR1C4
Aldo-keto reductase family 1, 
member C4 (chlordecone 
reductase; 3-alpha 
hydroxysteroid 
dehydrogenase, type I; 
dihydrodiol dehydrogenase 4)
-4,6 x
ENSG00000114771 AADAC Arylacetamide deacetylase (esterase) -5,3 x
ENSG00000116833 NR5A2 Nuclear receptor subfamily 5, group A, member 2 -5,4 x
ENSG00000187193 MT1X Metallothionein 1X -5,4 x
ENSG00000198417 MT1H Metallothionein 1H -2,9 -5,6 x
ENSG00000123838 C4BPA Complement component 4 binding protein, alpha -5,7 x
ENSG00000172955 ADH6 Alcohol dehydrogenase 6 (class V) -6,6 x
ENSG00000023839 ABCC2
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 2
-7,3 x
ENSG00000021461 CYP3A43 Cytochrome P450, family 3, subfamily A, polypeptide 43 -15,4 x
ENSG00000112337 SLC17A2
Solute carrier family 17 
(sodium phosphate), member 
2
-19,7 x
ENSG00000176153 GPX2 Glutathione peroxidase 2 (gastrointestinal) -3,9 -20,7 x
ENSG00000109758 HGFAC HGF activator -27,3 x
ENSG00000125551 PLGL Plasminogen-like B1 -2,7 x
ENSG00000125144 MT1G Metallothionein 1G -9,8 -6,8
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ENSG00000134538 SLCO1B1
Solute carrier organic anion 
transporter family, member 
1B1
-9,3 -14,7
ENSG00000172345 STARD5 START domain containing 5 -9,3 -2,5
ENSG00000132437 DDC Dopa decarboxylase (aromatic L-amino acid decarboxylase) -8,0 -10,5
ENSG00000135069 PSAT1 Phosphoserine aminotransferase 1 -6,4 -11,4
ENSG00000100558 PLEK2 Pleckstrin 2 -5,9 -2,6
ENSG00000160868 CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4 -4,5 -73,7
ENSG00000005187 SAH SA hypertension-associated homolog (rat) -4,3 -100,7
ENSG00000128266 GNAZ
Guanine nucleotide binding 
protein (G protein), alpha z 
polypeptide
-4,2
ENSG00000116717 GADD45A Growth arrest and DNA-damage-inducible, alpha -4,0
ENSG00000092621 PHGDH Phosphoglycerate dehydrogenase -3,8 -5,1
ENSG00000134470 IL15RA Interleukin 15 receptor, alpha -3,8
ENSG00000102078 SLC25A14
Solute carrier family 25 
(mitochondrial carrier, brain), 
member 14
-3,7
ENSG00000109667 SLC2A9
Solute carrier family 2 
(facilitated glucose 
transporter), member 9
-3,3
ENSG00000136689 IL1RN Interleukin 1 receptor antagonist -3,3 -3,0
ENSG00000127666 TRIF TIR domain containing adaptor inducing interferon-beta -3,2
ENSG00000145022 TCTA T-cell leukemia translocation altered gene -3,1
ENSG00000170345 FOS
V-fos FBJ murine 
osteosarcoma viral oncogene 
homolog
-3,1 -2,9
ENSG00000123454 DBH
Dopamine beta-hydroxylase 
(dopamine beta-
monooxygenase)
-3,1
ENSG00000130600 H19 H19, imprinted maternally expressed untranslated mRNA -3,1
ENSG00000131043 C20orf4 Chromosome 20 open reading frame 4 -3,0
ENSG00000010256 UQCRC1 Ubiquinol-cytochrome c reductase core protein I -2,9
ENSG00000171791 BCL2 B-cell CLL/lymphoma 2 -2,9
ENSG00000166741 NNMT Nicotinamide N-methyltransferase -2,7 -4,2
ENSG00000070087 PFN2 Profilin 2 -2,6 -2,8
ENSG00000196286
Monoclonal antibody HW1 
immunoglobulin light chain 
variable region
-2,4
ENSG00000104490 NCALD Neurocalcin delta -2,4 -2,7
ENSG00000171557 FGG Fibrinogen, gamma polypeptide -2,4
ENSG00000159423 ALDH4A1 Aldehyde dehydrogenase 4 family, member A1 -2,4 -3,7
ENSG00000077782 FGFR1
Fibroblast growth factor 
receptor 1 (fms-related 
tyrosine kinase 2, Pfeiffer 
syndrome)
-2,4
ENSG00000104760 FGL1 Fibrinogen-like 1 -2,3
ENSG00000125148 MT2A Metallothionein 2A -2,3 -3,8
ENSG00000096087 GSTA2 Glutathione S-transferase A2 -2,3
ENSG00000189221 MAOA Monoamine oxidase A -2,3 -3,0
ENSG00000148842 CNNM2 Cyclin M2 -2,2
ENSG00000087086 FTL Ferritin, light polypeptide -2,2 -2,0
ENSG00000171564 FGB Fibrinogen, B beta polypeptide -2,2 -20,0
ENSG00000121690 LOC91614 Novel 58.3 KDA protein -2,2
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ENSG00000085999 RAD54L RAD54-like (S. cerevisiae) -2,2
ENSG00000138794 CASP6 Caspase 6, apoptosis-related cysteine protease -2,1
ENSG00000146918 MTB Leucine zipper protein 5 -2,1
ENSG00000160310 HRMT1L1
HMT1 hnRNP 
methyltransferase-like 1 (S. 
cerevisiae)
-2,1
ENSG00000119686 C14orf58 Chromosome 14 open reading frame 58 -2,1
ENSG00000092529 CAPN3 Calpain 3, (p94) -2,0 -3,6
ENSG00000064995 TAF11
TAF11 RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
28kDa
-2,0
ENSG00000120896 SCAM-1 Vinexin beta (SH3-containing adaptor molecule-1) -2,0 -1,6
ENSG00000130707 ASS Argininosuccinate synthetase -2,0 -2,5
ENSG00000161267 BDH
3-hydroxybutyrate 
dehydrogenase (heart, 
mitochondrial)
-2,0 -3,6
ENSG00000177885 GRB2 Growth factor receptor-bound protein 2 -2,0
ENSG00000115414 FN1 Fibronectin 1 -2,0 -4,7
ENSG00000107745 CBARA1 Calcium binding atopy-related autoantigen 1 -2,0 -2,8
ENSG00000153707 PTPRD Protein tyrosine phosphatase, receptor type, D -2,0 -2,3
ENSG00000182979 MTA1 Metastasis associated 1 -2,0
ENSG00000102401 ARMCX3 Armadillo repeat containing, X-linked 3 -1,9 -1,4
ENSG00000157353 FUK Fucokinase -1,9
ENSG00000095203 EPB41L4B Erythrocyte membrane protein band 4.1 like 4B -1,9 -2,7
ENSG00000104635 SLC39A14 Solute carrier family 39 (zinc transporter), member 14 -1,9 -2,0
ENSG00000198270 LOC89894 Hypothetical protein BC000282 -1,9
ENSG00000163710 PCOLCE2 Procollagen C-endopeptidase enhancer 2 -1,9
ENSG00000106333 PCOLCE Procollagen C-endopeptidase enhancer -1,9
ENSG00000119938 PPP1R3C
Protein phosphatase 1, 
regulatory (inhibitor) subunit 
3C
-1,9
ENSG00000198960 ARMCX6 Armadillo repeat containing, X-linked 6 -1,9
ENSG00000145020 AMT
Aminomethyltransferase 
(glycine cleavage system 
protein T)
-1,9
ENSG00000119711 ALDH6A1 Aldehyde dehydrogenase 6 family, member A1 -1,9 -2,4
ENSG00000177853 ZNF518 Zinc finger protein 518 -1,8
ENSG00000116044 NFE2L2 Nuclear factor (erythroid-derived 2)-like 2 -1,8 -1,8
ENSG00000169692 AGPAT2
1-acylglycerol-3-phosphate O-
acyltransferase 2 
(lysophosphatidic acid 
acyltransferase, beta)
-1,8 -3,0
ENSG00000007565 DAXX Death-associated protein 6 -1,8
ENSG00000113269 RNF130 Ring finger protein 130 -1,8 -2,4
ENSG00000143369 ECM1 Extracellular matrix protein 1 -1,8 -3,3
ENSG00000162595 ARHI DIRAS family, GTP-binding RAS-like 3 -1,8 -2,3
ENSG00000125740 FOSB FBJ murine osteosarcoma viral oncogene homolog B -1,7 -3,2
ENSG00000148672 GLUD1 Glutamate dehydrogenase 1 -1,7 -2,9
ENSG00000100292 HMOX1 Heme oxygenase (decycling) 1 -1,7 -5,2
ENSG00000164039 DHRS6 Dehydrogenase/reductase (SDR family) member 6 -1,7 -2,6
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ENSG00000169136 ATF5 Activating transcription factor 5 -1,6 -2,7
ENSG00000156298 TM4SF2 Tetraspanin 7 -1,6 -2,3
ENSG00000100814 CCNB1IP1 Cyclin B1 interacting protein 1 -1,6 -4,2
ENSG00000066468 FGFR2
Fibroblast growth factor 
receptor 2 (bacteria-expressed 
kinase, keratinocyte growth 
factor receptor, craniofacial 
dysostosis 1, Crouzon 
syndrome, Pfeiffer syndrome, 
Jackson-Weiss syndrome)
-1,6 -2,2
ENSG00000171617 ENC1 Ectodermal-neural cortex (with BTB-like domain) -1,6 -1,9
ENSG00000133639 BTG1 B-cell translocation gene 1, anti-proliferative -1,6 -2,1
ENSG00000010810 FYN FYN oncogene related to SRC, FGR, YES -1,6 -3,6
ENSG00000117009 KMO Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) -1,5 -3,3
ENSG00000171793 CTPS CTP synthase -1,5 -4,4
ENSG00000116741 RGS2 Regulator of G-protein signalling 2, 24kDa -1,5 -2,5
ENSG00000159674 SPON2 Spondin 2, extracellular matrix protein -1,5 -2,0
ENSG00000182551 MTCBP-1
Membrane-type 1 matrix 
metalloproteinase cytoplasmic 
tail binding protein-1
-1,5 -1,8
ENSG00000100897 WDR23 WD repeat domain 23 -1,5 -1,8
ENSG00000162433 AK3 Adenylate kinase 3-like 1 -1,4 -2,2
ENSG00000142192 APP
Amyloid beta (A4) precursor 
protein (protease nexin-II, 
Alzheimer disease)
-1,4 -2,6
ENSG00000125520 SLC2A4RG SLC2A4 regulator -1,4 -2,2
ENSG00000109971 HSPA1B Heat shock 70kDa protein 1B -1,4 -2,8
ENSG00000065057 NTHL1 Nth endonuclease III-like 1 (E. coli) -1,4 -2,6
ENSG00000123843 C4BPB Complement component 4 binding protein, beta -1,4 -2,1
ENSG00000109861 CTSC Cathepsin C -1,4 -2,2
ENSG00000188042 ARL7 ADP-ribosylation factor-like 7 -1,4 -2,4
ENSG00000091490 KIAA0746 KIAA0746 protein -1,3 -2,0
ENSG00000178980 SEPW1 Selenoprotein W, 1 -1,3 -2,3
ENSG00000130475 FCHO1 FCH domain only 1 -1,3 -8,9
ENSG00000137124 ALDH1B1 Aldehyde dehydrogenase 1 family, member B1 -1,3 -3,2
ENSG00000197451 HNRPAB Heterogeneous nuclear ribonucleoprotein A/B 1,2 1,8
ENSG00000106992 AK1 Adenylate kinase 1 1,3 3,4
ENSG00000158864 NDUFS2
NADH dehydrogenase 
(ubiquinone) Fe-S protein 2, 
49kDa (NADH-coenzyme Q 
reductase)
1,3 1,9
ENSG00000105953 OGDH
Oxoglutarate (alpha-
ketoglutarate) dehydrogenase 
(lipoamide)
1,3 2,0
ENSG00000182054 IDH2 Isocitrate dehydrogenase 2 (NADP+), mitochondrial 1,3 1,9
ENSG00000161013 MGAT4B
Mannosyl (alpha-1,3-)-
glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, 
isoenzyme B
1,3 2,0
ENSG00000101940 WDR13 WD repeat domain 13 1,3 2,1
ENSG00000138073 PREB Prolactin regulatory element binding 1,4 2,2
ENSG00000121054 NME2 Non-metastatic cells 2, protein (NM23B) expressed in 1,4 1,9
ENSG00000103528 LOC51760 B/K protein 1,4 7,2
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ENSG00000185275 CD24 CD24 antigen (small cell lung carcinoma cluster 4 antigen) 1,4 3,6
ENSG00000110092 CCND1 Cyclin D1 (PRAD1: parathyroid adenomatosis 1) 1,4 3,6
ENSG00000161011 SQSTM1 Sequestosome 1 1,4 2,4
ENSG00000100504 PYGL
Phosphorylase, glycogen; liver 
(Hers disease, glycogen 
storage disease type VI)
1,4 2,2
ENSG00000166971 FTS Fused toes homolog (mouse) 1,4 2,1
ENSG00000117984 CTSD Cathepsin D (lysosomal aspartyl protease) 1,4 2,0
ENSG00000172115 CYCS Cytochrome c, somatic 1,4 2,0
ENSG00000125166 GOT2
Glutamic-oxaloacetic 
transaminase 2, mitochondrial 
(aspartate aminotransferase 2)
1,4 2,1
ENSG00000148334 PTGES2 Prostaglandin E synthase 2 1,4 2,0
ENSG00000064601 PPGB
Protective protein for beta-
galactosidase 
(galactosialidosis)
1,4 1,9
ENSG00000113645 KIBRA KIBRA protein 1,4 2,2
ENSG00000178558 CRI1 CREBBP/EP300 inhibitor 1 1,4 2,1
ENSG00000159840 ZYX Zyxin 1,4 1,8
ENSG00000120837 NFYB Nuclear transcription factor Y, beta 1,4 2,2
ENSG00000002822 MAD1L1 MAD1 mitotic arrest deficient-like 1 (yeast) 1,5 3,3
ENSG00000071051 NCK2 NCK adaptor protein 2 1,5 3,4
ENSG00000091409 ITGA6 Integrin, alpha 6 1,5 2,0
ENSG00000164120 HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 1,5 2,9
ENSG00000066322 ELOVL1
Elongation of very long chain 
fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 1
1,5 2,0
ENSG00000137403 HLA-F Major histocompatibility complex, class I, F 1,5 2,1
ENSG00000139641 MBC2
Family with sequence similarity 
62 (C2 domain containing), 
member A
1,5 1,8
ENSG00000198479 HLA-C Major histocompatibility complex, class I, C 1,5 2,4
ENSG00000110955 ATP5B
ATP synthase, H+ 
transporting, mitochondrial F1 
complex, beta polypeptide
1,6 2,1
ENSG00000145545 SRD5A1
Steroid-5-alpha-reductase, 
alpha polypeptide 1 (3-oxo-5 
alpha-steroid delta 4-
dehydrogenase alpha 1)
1,6 1,8
ENSG00000138074 SLC5A6
Solute carrier family 5 (sodium-
dependent vitamin 
transporter), member 6
1,6 2,5
ENSG00000119782 FKBP1B FK506 binding protein 1B, 12.6 kDa 1,7 69,0
ENSG00000131473 ACLY ATP citrate lyase 1,7 2,5
ENSG00000137259 HIST1H2AC Histone 1, H2ac 1,8 3,3
ENSG00000131759 RARA Retinoic acid receptor, alpha 1,8 1,9
ENSG00000124120 C20orf121 Chromosome 20 open reading frame 121 1,8 2,9
ENSG00000138131 LOXL4 Lysyl oxidase-like 4 1,8
ENSG00000144063 BENE BENE protein 1,8 3,7
ENSG00000143333 RGS16 Regulator of G-protein signalling 16 1,8 1,7
ENSG00000068793 CYFIP2 Cytoplasmic FMR1 interacting protein 2 1,8 4,9
ENSG00000130305 NSUN5 NOL1/NOP2/Sun domain family, member 5 1,8
ENSG00000120708 TGFBI Transforming growth factor, beta-induced, 68kDa 1,9 4,6
ENSG00000164830 OXR1 Oxidation resistance 1 1,9
ENSG00000115129 TP53I3 Tumor protein p53 inducible protein 3 1,9 4,9
ENSG00000147065 MSN Moesin 2,0 2,0
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ENSG00000013364 MVP Major vault protein 2,0 2,7
ENSG00000165731 RET
Ret proto-oncogene (multiple 
endocrine neoplasia and 
medullary thyroid carcinoma 1, 
Hirschsprung disease)
2,1 4,4
ENSG00000103042 FLJ10815 Amino acid transporter 2,1 2,7
ENSG00000132329 RAMP1 Receptor (calcitonin) activity modifying protein 1 2,2 2,8
ENSG00000129116 KIAA0992 Palladin 2,3 3,7
ENSG00000028310 BRD9 Bromodomain containing 9 2,3
ENSG00000112293 GPLD1 Glycosylphosphatidylinositol specific phospholipase D1 2,7 5,1
ENSG00000130294 KIF1A Kinesin family member 1A 2,7
ENSG00000134769 DTNA Dystrobrevin, alpha 2,9 2,2
ENSG00000049759 NEDD4L
Neural precursor cell 
expressed, developmentally 
down-regulated 4-like
3,2 3,7
ENSG00000160097 FNDC5 Fibronectin type III domain containing 5 3,3
ENSG00000008517 NK4 Interleukin 32 3,4
ENSG00000115875 SFRS7 Splicing factor, arginine/serine-rich 7, 35kDa 7,1
ENSG00000171819 ANGPTL7 Angiopoietin-like 7 10,0
ENSG00000160870 CYP3A7 Cytochrome P450, family 3, subfamily A, polypeptide 7 -1138,6
ENSG00000080345 RIF1 RAP1 interacting factor homolog (yeast) -538,1
ENSG00000123561 SERPINA7
Serine (or cysteine) proteinase 
inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), 
member 7
-500,0
ENSG00000169688 MT1K Metallothionein 1K -131,3
ENSG00000175003 SLC22A1
Solute carrier family 22 
(organic cation transporter), 
member 1
-86,0
ENSG00000049883 PTCD2 Pentatricopeptide repeat domain 2 -79,3
ENSG00000168259 DNAJC7 DnaJ (Hsp40) homolog, subfamily C, member 7 -70,0
ENSG00000167165 UGT1A6 UDP glycosyltransferase 1 family, polypeptide A9 -45,9
ENSG00000114200 BCHE Butyrylcholinesterase -39,9
ENSG00000129214 SHBG Sex hormone-binding globulin -27,8
ENSG00000158296 SLC13A3
Solute carrier family 13 
(sodium-dependent 
dicarboxylate transporter), 
member 3
-24,9
ENSG00000124713 GNMT Glycine N-methyltransferase -24,4
ENSG00000127831 VIL1 Villin 1 -23,8
ENSG00000100665 SERPINA4
Serine (or cysteine) proteinase 
inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), 
member 4
-22,8
ENSG00000160867 FGFR4 Fibroblast growth factor receptor 4 -21,7
ENSG00000160339 FCN2
Ficolin (collagen/fibrinogen 
domain containing lectin) 2 
(hucolin)
-20,8
ENSG00000157399 ARSE Arylsulfatase E (chondrodysplasia punctata 1) -20,8
ENSG00000173930 SLCO4C1
Solute carrier organic anion 
transporter family, member 
4C1
-20,4
ENSG00000164711 LPAL2 Lipoprotein, Lp(a)-like 2 -19,6
ENSG00000105701 FKBP8 FK506 binding protein 8, 38kDa -19,3
ENSG00000091972 CD200 CD200 antigen -19,2
ENSG00000125144 MT1F Metallothionein 1F (functional) -19,2
ENSG00000108187 MAWBP MAWD binding protein -19,1
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ENSG00000138079 SLC3A1
Solute carrier family 3 (cystine, 
dibasic and neutral amino acid 
transporters, activator of 
cystine, dibasic and neutral 
amino acid transport), member 
1
-18,1
ENSG00000183682 BMP8A Bone morphogenetic protein 8a -17,5
ENSG00000080709 KCNN2
Potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 
2
-16,2
ENSG00000086205 FOLH1 Folate hydrolase (prostate-specific membrane antigen) 1 -15,2
ENSG00000174156 GSTA3 Glutathione S-transferase A3 -15,0
ENSG00000138109 CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 9 -14,4
ENSG00000108231 LGI1 Leucine-rich, glioma inactivated 1 -13,5
ENSG00000163032 VSNL1 Visinin-like 1 -13,3
ENSG00000104938 CD209L C-type lectin domain family 4, member M -12,4
ENSG00000187097 ENTPD5 Ectonucleoside triphosphate diphosphohydrolase 5 -11,6
ENSG00000009694 CDNA clone IMAGE:4811759, partial cds -10,6
ENSG00000115919 KYNU Kynureninase (L-kynurenine hydrolase) -10,5
ENSG00000161270 PRODH2 Proline dehydrogenase (oxidase) 2 -9,3
ENSG00000135625 EGR4 Early growth response 4 -9,2
ENSG00000086300 SNX10 Sorting nexin 10 -9,0
ENSG00000165682 CLEC2 C-type lectin domain family 1, member B -7,4
ENSG00000175336 APOF Apolipoprotein F -7,2
ENSG00000067208 EVI5 Ecotropic viral integration site 5 -7,1
ENSG00000169715 MT1E Metallothionein 1E (functional) -6,1
ENSG00000162545 CaMKIINalpha Calcium/calmodulin-dependent protein kinase II -6,1
ENSG00000138640 FAM13A1 Family with sequence similarity 13, member A1 -5,9
ENSG00000114115 RBP1 Retinol binding protein 1, cellular -5,6
ENSG00000133800 XLKD1 Extracellular link domain containing 1 -5,5
ENSG00000184292 TACSTD2 Tumor-associated calcium signal transducer 2 -5,4
ENSG00000102891 MT4 Metallothionein IV -5,4
ENSG00000140465 CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 -5,3
ENSG00000188257 PLA2G2A Phospholipase A2, group IIA (platelets, synovial fluid) -5,2
ENSG00000159461 AMFR Autocrine motility factor receptor -5,2
ENSG00000139508 LOC283537 Hypothetical protein LOC283537 -5,2
ENSG00000075340 ADD2 Adducin 2 (beta) -5,1
ENSG00000142748 FCN3
Ficolin (collagen/fibrinogen 
domain containing) 3 (Hakata 
antigen)
-5,0
ENSG00000135423 GLS2 Glutaminase 2 (liver, mitochondrial) -5,0
ENSG00000136213 CHST12 Carbohydrate (chondroitin 4) sulfotransferase 12 -5,0
ENSG00000198805 NP Nucleoside phosphorylase -4,9
ENSG00000095596 CYP26A1 Cytochrome P450, family 26, subfamily A, polypeptide 1 -4,9
ENSG00000090512 FETUB Fetuin B -4,4
ENSG00000198670 LPA Lipoprotein, Lp(a) -4,3
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ENSG00000141338 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 -4,3
ENSG00000101057 MYBL2
V-myb myeloblastosis viral 
oncogene homolog (avian)-like 
2
-4,2
ENSG00000130227 XPO7 Exportin 7 -4,2
ENSG00000141293 SCAP1 Src family associated phosphoprotein 1 -4,2
ENSG00000166922 SGNE1
Secretory granule, 
neuroendocrine protein 1 (7B2 
protein)
-4,1
ENSG00000143627 PKLR Pyruvate kinase, liver and RBC -4,1
ENSG00000124568 SLC17A1
Solute carrier family 17 
(sodium phosphate), member 
1
-4,1
ENSG00000134363 FST Follistatin -4,0
ENSG00000110244 APOA4 Apolipoprotein A-IV -4,0
ENSG00000101349 PAK7 P21(CDKN1A)-activated kinase 7 -3,9
ENSG00000189013 KIR2DL4
Killer cell immunoglobulin-like 
receptor, two domains, long 
cytoplasmic tail, 4
-3,9
ENSG00000079805 DNM2 Dynamin 2 -3,8
ENSG00000153904 DDAH1 Dimethylarginine dimethylaminohydrolase 1 -3,8
ENSG00000120054 CPN1 Carboxypeptidase N, polypeptide 1, 50kD -3,8
ENSG00000136870 ZNF189 Zinc finger protein 189 -3,7
ENSG00000100031 GGTL4 Gamma-glutamyltransferase-like 4 -3,6
ENSG00000165507 C10orf10 Chromosome 10 open reading frame 10 -3,5
ENSG00000189056 RELN Reelin -3,5
ENSG00000143630 HCN3
Hyperpolarization activated 
cyclic nucleotide-gated 
potassium channel 3
-3,5
ENSG00000142494 FLJ10847 Hypothetical protein FLJ10847 -3,4
ENSG00000155666 FLJ13798 Hypothetical protein FLJ13798 -3,4
ENSG00000075651 PLD1 Phospholipase D1, phophatidylcholine-specific -3,4
ENSG00000101911 PRPS2 Phosphoribosyl pyrophosphate synthetase 2 -3,3
ENSG00000164647 STEAP Six transmembrane epithelial antigen of the prostate 1 -3,3
ENSG00000169032 MAP2K1 Mitogen-activated protein kinase kinase 1 -3,3
ENSG00000141179 PCTP Phosphatidylcholine transfer protein -3,2
ENSG00000145287 PLAC8 Placenta-specific 8 -3,2
ENSG00000087237 CETP Cholesteryl ester transfer protein, plasma -3,2
ENSG00000173610 UGT2A1 UDP glycosyltransferase 2 family, polypeptide A1 -3,1
ENSG00000013016 EHD3 EH-domain containing 3 -3,1
ENSG00000145824 CXCL14 Chemokine (C-X-C motif) ligand 14 -3,0
ENSG00000141441 C18orf11 Family with sequence similarity 59, member A -3,0
ENSG00000143507 DUSP10 Dual specificity phosphatase 10 -2,9
ENSG00000070729 CNGB1 Cyclic nucleotide gated channel beta 1 -2,9
ENSG00000165140 FBP1 Fructose-1,6-bisphosphatase 1 -2,9
ENSG00000100031 GGT1 Gamma-glutamyltransferase 1 -2,8
ENSG00000182890 GLUD2 Glutamate dehydrogenase 2 -2,8
ENSG00000135226 UGT2B28 UDP glycosyltransferase 2 family, polypeptide B28 -2,8
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ENSG00000113196 HAND1 Heart and neural crest derivatives expressed 1 -2,8
ENSG00000115525 SIAT9 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 -2,8
ENSG00000137561 TTPA
Tocopherol (alpha) transfer 
protein (ataxia (Friedreich-like) 
with vitamin E deficiency)
-2,8
ENSG00000161574 CCL15 Chemokine (C-C motif) ligand 14 -2,8
ENSG00000163687 DNASE1L3 Deoxyribonuclease I-like 3 -2,8
ENSG00000168421 RHOH Ras homolog gene family, member H -2,8
ENSG00000072694 FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32) -2,7
ENSG00000159723 AGRP Agouti related protein homolog (mouse) -2,7
ENSG00000092820 VIL2 Villin 2 (ezrin) -2,7
ENSG00000131018 SYNE1 Spectrin repeat containing, nuclear envelope 1 -2,6
ENSG00000108479 GALK1 Galactokinase 1 -2,6
ENSG00000095739 BAMBI
BMP and activin membrane-
bound inhibitor homolog 
(Xenopus laevis)
-2,6
ENSG00000185650 ZFP36L1 Zinc finger protein 36, C3H type-like 1 -2,6
ENSG00000116761 CTH Cystathionase (cystathionine gamma-lyase) -2,6
ENSG00000101856 PGRMC1 Progesterone receptor membrane component 1 -2,6
ENSG00000165475 CRYL1 Crystallin, lambda 1 -2,6
ENSG00000139289 PHLDA1 Pleckstrin homology-like domain, family A, member 1 -2,6
ENSG00000117479 SLC19A2
Solute carrier family 19 
(thiamine transporter), member 
2
-2,5
ENSG00000119866 BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) -2,5
ENSG00000010327 STAB1 Stabilin 1 -2,5
ENSG00000196177 ACADSB
Acyl-Coenzyme A 
dehydrogenase, 
short/branched chain
-2,5
ENSG00000151422 FER
Fer (fps/fes related) tyrosine 
kinase (phosphoprotein 
NCP94)
-2,5
ENSG00000152558 PORIMIN Pro-oncosis receptor inducing membrane injury gene -2,4
ENSG00000103200 NME4 Non-metastatic cells 4, protein expressed in -2,4
ENSG00000060762 BRP44L Brain protein 44-like -2,4
ENSG00000175806 MSRA Methionine sulfoxide reductase A -2,4
ENSG00000117983 MUC5AC Mucin 5, subtypes A and C, tracheobronchial/gastric -2,4
ENSG00000129007 CALML4 Calmodulin-like 4 -2,4
ENSG00000106025 TM4SF12 Tetraspanin 12 -2,4
ENSG00000096395 MLN Motilin -2,4
ENSG00000185000 DGAT1
Diacylglycerol O-
acyltransferase homolog 1 
(mouse)
-2,4
ENSG00000124374 KIAA1155 KIAA1155 protein -2,4
ENSG00000114698 PLSCR4 Phospholipid scramblase 4 -2,4
ENSG00000131171 SH3BGRL SH3 domain binding glutamic acid-rich protein like -2,4
ENSG00000117036 ETV3 Ets variant gene 3 -2,3
ENSG00000197747 S100A10
S100 calcium binding protein 
A10 (annexin II ligand, 
calpactin I, light polypeptide 
(p11))
-2,3
ENSG00000135318 NT5E 5'-nucleotidase, ecto (CD73) -2,3
ENSG00000144035 NAT8 N-acetyltransferase 8 (camello like) -2,3
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ENSG00000133983 C14orf112 Chromosome 14 open reading frame 112 -2,3
ENSG00000132207 SULT1A3
Sulfotransferase family, 
cytosolic, 1A, phenol-
preferring, member 3
-2,3
ENSG00000138744 ASAHL
N-acylsphingosine 
amidohydrolase (acid 
ceramidase)-like
-2,3
ENSG00000170458 CD14 CD14 antigen -2,3
ENSG00000112494 UNC93A Unc-93 homolog A (C. elegans) -2,3
ENSG00000148468 C10orf38 Chromosome 10 open reading frame 38 -2,3
ENSG00000102897 LOC57149 Hypothetical protein A-211C6.1 -2,3
ENSG00000071894 CPSF1 Cleavage and polyadenylation specific factor 1, 160kDa -2,3
ENSG00000105852 PON3 Paraoxonase 3 -2,3
ENSG00000137414 FAM8A1 Family with sequence similarity 8, member A1 -2,3
ENSG00000110011 DNAJC4 DnaJ (Hsp40) homolog, subfamily C, member 4 -2,2
ENSG00000156113 KCNMA1
Potassium large conductance 
calcium-activated channel, 
subfamily M, alpha member 1
-2,2
ENSG00000112769 LAMA4 Laminin, alpha 4 -2,2
ENSG00000197114 FLJ20406 Lck interacting transmembrane adaptor 1 -2,2
ENSG00000083857 FAT FAT tumor suppressor homolog 1 (Drosophila) -2,2
ENSG00000143845 ETNK2 Ethanolamine kinase 2 -2,2
ENSG00000123500 COL10A1
Collagen, type X, alpha 
1(Schmid metaphyseal 
chondrodysplasia)
-2,2
ENSG00000100116 GCAT
Glycine C-acetyltransferase (2-
amino-3-ketobutyrate 
coenzyme A ligase)
-2,2
ENSG00000085465 OVGP1 Oviductal glycoprotein 1, 120kDa (mucin 9, oviductin) -2,2
ENSG00000197321 SVIL Supervillin -2,1
ENSG00000176170 SPHK1 Sphingosine kinase 1 -2,1
ENSG00000197165 SULT1A2
Sulfotransferase family, 
cytosolic, 1A, phenol-
preferring, member 2
-2,1
ENSG00000101577 LPIN2 Lipin 2 -2,1
ENSG00000130522 JUND Jun D proto-oncogene -2,1
ENSG00000146674 IGFBP3 Insulin-like growth factor binding protein 3 -2,1
ENSG00000170430 MGMT O-6-methylguanine-DNA methyltransferase -2,1
ENSG00000137960 GIPC2 PDZ domain protein GIPC2 -2,1
ENSG00000105711 SCN1B Sodium channel, voltage-gated, type I, beta -2,1
ENSG00000072840 EVC Ellis van Creveld syndrome -2,1
ENSG00000149435 GGTLA4 Gamma-glutamyltransferase-like activity 4 -2,1
ENSG00000130076 IGHG3 Immunoglobulin heavy constant mu -2,1
ENSG00000147394 ZNF185 Zinc finger protein 185 (LIM domain) -2,1
ENSG00000160973 FOXH1 Forkhead box H1 -2,1
ENSG00000169951 MGC13138 Hypothetical protein MGC13138 -2,0
ENSG00000123496 IL13RA2 Interleukin 13 receptor, alpha 2 -2,0
ENSG00000152104 PTPN14 Protein tyrosine phosphatase, non-receptor type 14 -2,0
ENSG00000149084 HSD17B12 Hydroxysteroid (17-beta) dehydrogenase 12 -2,0
ENSG00000082438 COBLL1 COBL-like 1 -2,0
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ENSG00000182165 TP53AP1 TP53 activated protein 1 -2,0
ENSG00000173918 C1QTNF1 C1q and tumor necrosis factor related protein 1 -2,0
ENSG00000137992 DBT Dihydrolipoamide branched chain transacylase E2 -2,0
ENSG00000167800 TBX10 T-box 10 -2,0
ENSG00000159200 DSCR1 Down syndrome critical region gene 1 -2,0
ENSG00000023330 ALAS1 Aminolevulinate, delta-, synthase 1 -2,0
ENSG00000160862 AZGP1 Alpha-2-glycoprotein 1, zinc -2,0
ENSG00000151224 MAT1A Methionine adenosyltransferase I, alpha -2,0
ENSG00000178075 GRAMD1C GRAM domain containing 1C -1,9
ENSG00000171067 C11orf24 Chromosome 11 open reading frame 24 -1,9
ENSG00000137642 SORL1 Sortilin-related receptor, L(DLR class) A repeats-containing -1,9
ENSG00000197114 ZGPAT Zinc finger, CCCH-type with G patch domain -1,9
ENSG00000166886 NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) -1,9
ENSG00000109814 UGDH UDP-glucose dehydrogenase -1,9
ENSG00000096141 LY6G6D Chromosome 6 open reading frame 21 -1,9
ENSG00000142634 EFHD2 EF hand domain family, member D2 -1,9
ENSG00000143815 LBR Lamin B receptor -1,9
ENSG00000102934 TM4SF11 Plasma membrane proteolipid (plasmolipin) -1,8
ENSG00000102010 BMX BMX non-receptor tyrosine kinase -1,8
ENSG00000100321 SYNGR1 Synaptogyrin 1 -1,8
ENSG00000143793 C1orf35 Chromosome 1 open reading frame 35 -1,8
ENSG00000178105 DDX10 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 -1,8
ENSG00000137699 TRIM29 Tripartite motif-containing 29 -1,8
ENSG00000140575 IQGAP1 IQ motif containing GTPase activating protein 1 -1,8
ENSG00000139644 TEGT Testis enhanced gene transcript (BAX inhibitor 1) -1,8
ENSG00000140459 CYP11A1 Cytochrome P450, family 11, subfamily A, polypeptide 1 -1,6
ENSG00000069966 GNB5 Guanine nucleotide binding protein (G protein), beta 5 1,8
ENSG00000099290 RP11-56A21.1 Similar to KIAA0592 protein 1,8
ENSG00000111711 CGI-141 Golgi transport 1 homolog B (S. cerevisiae) 1,8
ENSG00000122873 C10orf70 Chromosome 10 open reading frame 70 1,8
ENSG00000136986 DERL1 Der1-like domain family, member 1 1,9
ENSG00000023228 NDUFS1
NADH dehydrogenase 
(ubiquinone) Fe-S protein 1, 
75kDa (NADH-coenzyme Q 
reductase)
1,9
ENSG00000174640 SLCO2A1
Solute carrier organic anion 
transporter family, member 
2A1
1,9
ENSG00000172731 LRRC20 Leucine rich repeat containing 20 1,9
ENSG00000143061 IGSF3 Immunoglobulin superfamily, member 3 1,9
ENSG00000173660 UQCRH Ubiquinol-cytochrome c reductase hinge protein 1,9
ENSG00000106052 TAX1BP1 Tax1 (human T-cell leukemia virus type I) binding protein 1 1,9
ENSG00000178234 GALNT11
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferas
e 11 (GalNAc-T11)
1,9
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ENSG00000111801 BTN3A3 Butyrophilin, subfamily 3, member A3 1,9
ENSG00000137204 SLC22A7
Solute carrier family 22 
(organic anion transporter), 
member 7
1,9
ENSG00000113108 APBB3
Amyloid beta (A4) precursor 
protein-binding, family B, 
member 3
2,0
ENSG00000196655 TRAPPC4 Trafficking protein particle complex 4 2,0
ENSG00000180304 OAZ2 Ornithine decarboxylase antizyme 2 2,0
ENSG00000109654 TRIM2 Tripartite motif-containing 2 2,0
ENSG00000108641 EPPB9 B9 protein 2,0
ENSG00000149485 FADS1 Fatty acid desaturase 1 2,0
ENSG00000197597 H2BFS H2B histone family, member S 2,0
ENSG00000049541 RFC2 Replication factor C (activator 1) 2, 40kDa 2,0
ENSG00000139190 VAMP1 Vesicle-associated membrane protein 1 (synaptobrevin 1) 2,0
ENSG00000187758 ADH1C Alcohol dehydrogenase 1C (class I), gamma polypeptide 2,0
ENSG00000198793 FRAP1 FK506 binding protein 12-rapamycin associated protein 1 2,0
ENSG00000196700 SOX18 SRY (sex determining region Y)-box 18 2,1
ENSG00000125967 APBA2BP
Amyloid beta (A4) precursor 
protein-binding, family A, 
member 2 binding protein
2,1
ENSG00000117289 TXNIP Thioredoxin interacting protein 2,1
ENSG00000172292 LASS6 LAG1 longevity assurance homolog 6 (S. cerevisiae) 2,1
ENSG00000168061 SHD1 SAC3 domain containing 1 2,1
ENSG00000168899 VAMP5 Vesicle-associated membrane protein 5 (myobrevin) 2,1
ENSG00000105854 PON2 Paraoxonase 2 2,1
ENSG00000197635 DPP4
Dipeptidylpeptidase 4 (CD26, 
adenosine deaminase 
complexing protein 2)
2,1
ENSG00000134698 EIF2C4 Eukaryotic translation initiation factor 2C, 4 2,2
ENSG00000012660 ELOVL5
ELOVL family member 5, 
elongation of long chain fatty 
acids (FEN1/Elo2, SUR4/Elo3-
like, yeast)
2,2
ENSG00000137575 SDCBP Syndecan binding protein (syntenin) 2,2
ENSG00000140939 NOL3 Nucleolar protein 3 (apoptosis repressor with CARD domain) 2,2
ENSG00000066044 ELAVL1
ELAV (embryonic lethal, 
abnormal vision, Drosophila)-
like 1 (Hu antigen R)
2,2
ENSG00000144749 LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 2,2
ENSG00000197694 SPTAN1 Spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 2,2
ENSG00000186480 INSIG1 Insulin induced gene 1 2,2
ENSG00000100029 PES1
Pescadillo homolog 1, 
containing BRCT domain 
(zebrafish)
2,3
ENSG00000068745 IHPK2 Inositol hexaphosphate kinase 2 2,3
ENSG00000138821 SLC39A8 Solute carrier family 39 (zinc transporter), member 8 2,3
ENSG00000197499 HLA-A Major histocompatibility complex, class I, A 2,3
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ENSG00000131773 KHDRBS3
KH domain containing, RNA 
binding, signal transduction 
associated 3
2,3
ENSG00000183087 GAS6 Growth arrest-specific 6 2,3
ENSG00000072042 RDH11 DKFZP564M1462 protein 2,3
ENSG00000072682 P4HA2
Procollagen-proline, 2-
oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 
polypeptide II
2,3
ENSG00000133131 ZCWCC2 Zinc finger, CW type with coiled-coil domain 2 2,3
ENSG00000143643 TTC13 Tetratricopeptide repeat domain 13 2,3
ENSG00000178878 DKFZP434F0318 Hypothetical protein DKFZp434F0318 2,3
ENSG00000188126 MYO15B Myosin XVB, pseudogene 2,3
ENSG00000188301 PDGFA Platelet-derived growth factor alpha polypeptide 2,3
ENSG00000110852 CLECSF2 C-type lectin domain family 2, member B 2,3
ENSG00000101782 RIOK3 RIO kinase 3 (yeast) 2,3
ENSG00000176887 SOX11 SRY (sex determining region Y)-box 11 2,3
ENSG00000138193 PLCE1 Phospholipase C, epsilon 1 2,3
ENSG00000008283 CYB561 Cytochrome b-561 2,4
ENSG00000176658 MYO1D Myosin ID 2,4
ENSG00000198758 EPS8L3 EPS8-like 3 2,4
ENSG00000100941 PNN Pinin, desmosome associated protein 2,4
ENSG00000025708 ECGF1 Endothelial cell growth factor 1 (platelet-derived) 2,4
ENSG00000118804 GENX-3414 Genethonin 1 2,4
ENSG00000113732 ATP6V0E ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e 2,4
ENSG00000158321 AUTS2 Autism susceptibility candidate 2 2,4
ENSG00000140092 FBLN5 Fibulin 5 2,4
ENSG00000078114 NEBL Nebulette 2,4
ENSG00000150403 C13orf11 Chromosome 13 open reading frame 11 2,4
ENSG00000123240 OPTN Optineurin 2,5
ENSG00000124635 HIST1H2BK Histone 1, H2bk 2,5
ENSG00000156831 FLJ32440 Hypothetical protein FLJ32440 2,5
ENSG00000114251 WNT5A
Wingless-type MMTV 
integration site family, member 
5A
2,5
ENSG00000198586 TLK1 Tousled-like kinase 1 2,5
ENSG00000075151 EIF4G3 Eukaryotic translation initiation factor 4 gamma, 3 2,5
ENSG00000011052 NME1 Non-metastatic cells 1, protein (NM23A) expressed in 2,6
ENSG00000198872 PEG10 Paternally expressed 10 2,6
ENSG00000050165 DKK3 Dickkopf homolog 3 (Xenopus laevis) 2,6
ENSG00000140632 N-PAC Cytokine-like nuclear factor n-pac 2,7
ENSG00000198722 UNC13B Unc-13 homolog B (C. elegans) 2,7
ENSG00000005471 ABCB4
ATP-binding cassette, sub-
family B (MDR/TAP), member 
4
2,7
ENSG00000073008 PVR Poliovirus receptor 2,7
ENSG00000168242 HIST1H2BH Histone 1, H2bh 2,8
ENSG00000149554 CHEK1 CHK1 checkpoint homolog (S. pombe) 2,8
ENSG00000103657 HERC1
Hect (homologous to the E6-
AP (UBE3A) carboxyl 
terminus) domain and RCC1 
(CHC1)-like domain (RLD) 1
2,8
ENSG00000187164 KIAA1598 KIAA1598 2,9
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ENSG00000136854 STXBP1 Syntaxin binding protein 1 3,0
ENSG00000101849 TBL1X Transducin (beta)-like 1X-linked 3,1
ENSG00000198730 SH2BP1
SH2 domain binding protein 1 
(tetratricopeptide repeat 
containing)
3,1
ENSG00000129538 RNASE1 Ribonuclease, RNase A family, 1 (pancreatic) 3,2
ENSG00000141447 OSBPL1A Oxysterol binding protein-like 1A 3,2
ENSG00000146904 EPHA1 EPH receptor A1 3,2
ENSG00000112378 PERP PERP, TP53 apoptosis effector 3,2
ENSG00000134324 LPIN1 Lipin 1 3,2
ENSG00000166033 PRSS11 Protease, serine, 11 (IGF binding) 3,3
ENSG00000160752 FDPS
Farnesyl diphosphate synthase 
(farnesyl pyrophosphate 
synthetase, 
dimethylallyltranstransferase, 
geranyltranstransferase)
3,4
ENSG00000107518 ATRNL1 Attractin-like 1 3,5
ENSG00000173698 GPR64 G protein-coupled receptor 64 3,5
ENSG00000100297 MCM5
MCM5 minichromosome 
maintenance deficient 5, cell 
division cycle 46 (S. 
cerevisiae)
3,5
ENSG00000145730 PAM Peptidylglycine alpha-amidating monooxygenase 3,6
ENSG00000196187 TMEM63A Transmembrane protein 63A 3,6
ENSG00000141736 ERBB2
V-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 2, neuro/glioblastoma 
derived oncogene homolog 
(avian)
3,6
ENSG00000148180 GSN Gelsolin (amyloidosis, Finnish type) 3,7
ENSG00000184115 LOC440895 Similar to LIM and senescent cell antigen-like domains 3 3,8
ENSG00000184304 PRKD1 Protein kinase D1 4,0
ENSG00000160202 CRYAA Crystallin, alpha A 4,2
ENSG00000162909 CAPN2 Calpain 2, (m/II) large subunit 4,3
ENSG00000164035 EMCN Endomucin 4,4
ENSG00000112320 FLJ10159 Hypothetical protein FLJ10159 4,5
ENSG00000128284 APOL3 Apolipoprotein L, 3 4,5
ENSG00000133985 TTC9 Tetratricopeptide repeat domain 9 4,7
ENSG00000175054 ATR Ataxia telangiectasia and Rad3 related 4,8
ENSG00000105499 PLA2G4C
Phospholipase A2, group IVC 
(cytosolic, calcium-
independent)
5,0
ENSG00000130300 PLVAP Plasmalemma vesicle associated protein 5,3
ENSG00000177697 CD151 CD151 antigen 5,3
ENSG00000047597 XK Kell blood group precursor (McLeod phenotype) 5,9
ENSG00000116661 FBXO2 F-box protein 2 6,1
ENSG00000163993 S100P S100 calcium binding protein P 8,2
ENSG00000197402 UBD Ubiquitin D 8,7
ENSG00000163923 RPL39L Ribosomal protein L39-like 8,8
ENSG00000144476 CMKOR1 Chemokine orphan receptor 1 8,9
ENSG00000021645 NRXN1 Neurexin 1 9,5
ENSG00000138028 CGREF1 Cell growth regulator with EF hand domain 1 9,6
ENSG00000101210 EEF1A2 Eukaryotic translation elongation factor 1 alpha 2 10,6
ENSG00000148634 HERC4 Hect domain and RLD 4 13,9
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ENSG00000185697 MYBL1
V-myb myeloblastosis viral 
oncogene homolog (avian)-like 
1
15,2
ENSG00000066279 ASPM
Asp (abnormal spindle)-like, 
microcephaly associated 
(Drosophila)
16,6
ENSG00000198000 NOL8 Nucleolar protein 8 19,6
ENSG00000204291 COL15A1 Collagen, type XV, alpha 1 25,8
ENSG00000110799 VWF Von Willebrand factor 38,2
ENSG00000100311 PDGFB
Platelet-derived growth factor 
beta polypeptide (simian 
sarcoma viral (v-sis) oncogene 
homolog)
44,0
ENSG00000133048 CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) 96,3
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